WO1999045123A1 - Recombinant staphylococcus thioredoxin reductase, and inhibitors thereof useful as antimicrobial agents - Google Patents
Recombinant staphylococcus thioredoxin reductase, and inhibitors thereof useful as antimicrobial agents Download PDFInfo
- Publication number
- WO1999045123A1 WO1999045123A1 PCT/US1999/004512 US9904512W WO9945123A1 WO 1999045123 A1 WO1999045123 A1 WO 1999045123A1 US 9904512 W US9904512 W US 9904512W WO 9945123 A1 WO9945123 A1 WO 9945123A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- trxb
- staphylococcus
- polypeptide
- polynucleotide
- test sample
- Prior art date
Links
- 241000191940 Staphylococcus Species 0.000 title claims abstract description 74
- 102000013090 Thioredoxin-Disulfide Reductase Human genes 0.000 title claims abstract description 20
- 108010079911 Thioredoxin-disulfide reductase Proteins 0.000 title claims abstract description 20
- 239000003112 inhibitor Substances 0.000 title description 8
- 239000004599 antimicrobial Substances 0.000 title description 6
- 238000000034 method Methods 0.000 claims abstract description 80
- 108091033319 polynucleotide Proteins 0.000 claims abstract description 59
- 102000040430 polynucleotide Human genes 0.000 claims abstract description 59
- 239000002157 polynucleotide Substances 0.000 claims abstract description 59
- 230000000694 effects Effects 0.000 claims abstract description 38
- 238000012360 testing method Methods 0.000 claims abstract description 38
- 150000001875 compounds Chemical class 0.000 claims abstract description 35
- 239000013598 vector Substances 0.000 claims abstract description 32
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 62
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 60
- 239000000523 sample Substances 0.000 claims description 60
- 229920001184 polypeptide Polymers 0.000 claims description 57
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 47
- 108060008226 thioredoxin Proteins 0.000 claims description 42
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 claims description 30
- 102000004877 Insulin Human genes 0.000 claims description 25
- 108090001061 Insulin Proteins 0.000 claims description 25
- 229940125396 insulin Drugs 0.000 claims description 25
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 claims description 25
- 102000002933 Thioredoxin Human genes 0.000 claims description 24
- 239000000203 mixture Substances 0.000 claims description 24
- 150000007523 nucleic acids Chemical class 0.000 claims description 24
- 229940094937 thioredoxin Drugs 0.000 claims description 24
- 125000003729 nucleotide group Chemical group 0.000 claims description 21
- 230000009467 reduction Effects 0.000 claims description 21
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 20
- 102000039446 nucleic acids Human genes 0.000 claims description 20
- 108020004707 nucleic acids Proteins 0.000 claims description 20
- 239000002773 nucleotide Substances 0.000 claims description 20
- 239000000758 substrate Substances 0.000 claims description 20
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 claims description 18
- 108020005187 Oligonucleotide Probes Proteins 0.000 claims description 15
- 239000002751 oligonucleotide probe Substances 0.000 claims description 15
- 239000000284 extract Substances 0.000 claims description 12
- 208000015181 infectious disease Diseases 0.000 claims description 12
- 238000004113 cell culture Methods 0.000 claims description 7
- 238000002405 diagnostic procedure Methods 0.000 claims description 7
- 125000003396 thiol group Chemical group [H]S* 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 238000012544 monitoring process Methods 0.000 claims description 5
- 230000003647 oxidation Effects 0.000 claims description 5
- 238000007254 oxidation reaction Methods 0.000 claims description 5
- 238000001641 gel filtration chromatography Methods 0.000 claims description 4
- 230000000844 anti-bacterial effect Effects 0.000 claims description 3
- 150000002019 disulfides Chemical class 0.000 claims description 3
- 238000013518 transcription Methods 0.000 claims description 3
- 230000035897 transcription Effects 0.000 claims description 3
- 206010041925 Staphylococcal infections Diseases 0.000 claims description 2
- 238000005571 anion exchange chromatography Methods 0.000 claims description 2
- 230000006920 protein precipitation Effects 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 208000015339 staphylococcus aureus infection Diseases 0.000 claims 1
- 238000012216 screening Methods 0.000 abstract description 5
- 102000004190 Enzymes Human genes 0.000 description 45
- 108090000790 Enzymes Proteins 0.000 description 45
- 229940088598 enzyme Drugs 0.000 description 45
- 210000004027 cell Anatomy 0.000 description 42
- 108020004414 DNA Proteins 0.000 description 39
- 108090000623 proteins and genes Proteins 0.000 description 39
- 239000013612 plasmid Substances 0.000 description 38
- 101150057627 trxB gene Proteins 0.000 description 29
- 238000006243 chemical reaction Methods 0.000 description 28
- 239000012634 fragment Substances 0.000 description 24
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 22
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 22
- 102100036407 Thioredoxin Human genes 0.000 description 18
- 238000003752 polymerase chain reaction Methods 0.000 description 18
- 235000001014 amino acid Nutrition 0.000 description 17
- 229940024606 amino acid Drugs 0.000 description 17
- 239000000872 buffer Substances 0.000 description 17
- 241000894006 Bacteria Species 0.000 description 16
- 241000191963 Staphylococcus epidermidis Species 0.000 description 16
- 230000001580 bacterial effect Effects 0.000 description 15
- 235000018102 proteins Nutrition 0.000 description 15
- 102000004169 proteins and genes Human genes 0.000 description 15
- 150000001413 amino acids Chemical class 0.000 description 14
- 238000003556 assay Methods 0.000 description 14
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 12
- 230000014509 gene expression Effects 0.000 description 12
- 239000013615 primer Substances 0.000 description 12
- KIUMMUBSPKGMOY-UHFFFAOYSA-N 3,3'-Dithiobis(6-nitrobenzoic acid) Chemical compound C1=C([N+]([O-])=O)C(C(=O)O)=CC(SSC=2C=C(C(=CC=2)[N+]([O-])=O)C(O)=O)=C1 KIUMMUBSPKGMOY-UHFFFAOYSA-N 0.000 description 11
- 241000588724 Escherichia coli Species 0.000 description 11
- 230000001419 dependent effect Effects 0.000 description 11
- 229960003276 erythromycin Drugs 0.000 description 11
- 229960003180 glutathione Drugs 0.000 description 11
- 238000009396 hybridization Methods 0.000 description 11
- 238000010367 cloning Methods 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 9
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 9
- 235000011130 ammonium sulphate Nutrition 0.000 description 9
- 238000005119 centrifugation Methods 0.000 description 9
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 8
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 230000002759 chromosomal effect Effects 0.000 description 8
- 230000002829 reductive effect Effects 0.000 description 8
- 230000010076 replication Effects 0.000 description 8
- 108091026890 Coding region Proteins 0.000 description 7
- 108091028043 Nucleic acid sequence Proteins 0.000 description 7
- 108700026244 Open Reading Frames Proteins 0.000 description 7
- 241000295644 Staphylococcaceae Species 0.000 description 7
- 238000007792 addition Methods 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 238000000746 purification Methods 0.000 description 7
- 238000000926 separation method Methods 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 239000001974 tryptic soy broth Substances 0.000 description 7
- 108010050327 trypticase-soy broth Proteins 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 239000004098 Tetracycline Substances 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 230000001413 cellular effect Effects 0.000 description 6
- 238000004587 chromatography analysis Methods 0.000 description 6
- 235000018417 cysteine Nutrition 0.000 description 6
- 125000000151 cysteine group Chemical class N[C@@H](CS)C(=O)* 0.000 description 6
- 238000002523 gelfiltration Methods 0.000 description 6
- 238000003780 insertion Methods 0.000 description 6
- 230000037431 insertion Effects 0.000 description 6
- 244000005700 microbiome Species 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 229960002180 tetracycline Drugs 0.000 description 6
- 229930101283 tetracycline Natural products 0.000 description 6
- 235000019364 tetracycline Nutrition 0.000 description 6
- 150000003522 tetracyclines Chemical class 0.000 description 6
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 5
- 102100036442 Glutathione reductase, mitochondrial Human genes 0.000 description 5
- 206010040070 Septic Shock Diseases 0.000 description 5
- 238000002835 absorbance Methods 0.000 description 5
- 210000004899 c-terminal region Anatomy 0.000 description 5
- 210000000349 chromosome Anatomy 0.000 description 5
- 239000002299 complementary DNA Substances 0.000 description 5
- -1 ethanol Chemical compound 0.000 description 5
- 230000002779 inactivation Effects 0.000 description 5
- 210000004962 mammalian cell Anatomy 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 238000001556 precipitation Methods 0.000 description 5
- 108091008146 restriction endonucleases Proteins 0.000 description 5
- 238000012163 sequencing technique Methods 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 5
- 230000009466 transformation Effects 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- 229920000936 Agarose Polymers 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 102000053602 DNA Human genes 0.000 description 4
- 241000192125 Firmicutes Species 0.000 description 4
- 108010024636 Glutathione Proteins 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 108091034117 Oligonucleotide Proteins 0.000 description 4
- 230000003321 amplification Effects 0.000 description 4
- 229940098773 bovine serum albumin Drugs 0.000 description 4
- 230000003197 catalytic effect Effects 0.000 description 4
- 239000013599 cloning vector Substances 0.000 description 4
- 238000010276 construction Methods 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000010354 integration Effects 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 238000003199 nucleic acid amplification method Methods 0.000 description 4
- 238000010647 peptide synthesis reaction Methods 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 108091006522 Anion exchangers Proteins 0.000 description 3
- 229920002307 Dextran Polymers 0.000 description 3
- 238000009007 Diagnostic Kit Methods 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 108090000988 Lysostaphin Proteins 0.000 description 3
- 102000004316 Oxidoreductases Human genes 0.000 description 3
- 108090000854 Oxidoreductases Proteins 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 3
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 239000000710 homodimer Substances 0.000 description 3
- 210000004408 hybridoma Anatomy 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 229920002401 polyacrylamide Polymers 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 230000006798 recombination Effects 0.000 description 3
- 238000005215 recombination Methods 0.000 description 3
- 230000036303 septic shock Effects 0.000 description 3
- 239000007790 solid phase Substances 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 102000007698 Alcohol dehydrogenase Human genes 0.000 description 2
- 108010021809 Alcohol dehydrogenase Proteins 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 208000031729 Bacteremia Diseases 0.000 description 2
- 206010005940 Bone and joint infections Diseases 0.000 description 2
- 241000701822 Bovine papillomavirus Species 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 241000701022 Cytomegalovirus Species 0.000 description 2
- 229920002271 DEAE-Sepharose Polymers 0.000 description 2
- 230000006820 DNA synthesis Effects 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 206010014568 Empyema Diseases 0.000 description 2
- 241001198387 Escherichia coli BL21(DE3) Species 0.000 description 2
- 108700039887 Essential Genes Proteins 0.000 description 2
- 241000206602 Eukaryota Species 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 208000005577 Gastroenteritis Diseases 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 2
- 201000009906 Meningitis Diseases 0.000 description 2
- 238000010222 PCR analysis Methods 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical class C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 108091028664 Ribonucleotide Proteins 0.000 description 2
- 108010041388 Ribonucleotide Reductases Proteins 0.000 description 2
- 102000000505 Ribonucleotide Reductases Human genes 0.000 description 2
- 208000021326 Ritter disease Diseases 0.000 description 2
- 241000714474 Rous sarcoma virus Species 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- 238000012300 Sequence Analysis Methods 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 108020004682 Single-Stranded DNA Proteins 0.000 description 2
- 206010041929 Staphylococcal scalded skin syndrome Diseases 0.000 description 2
- 241000823609 Staphylococcus aureus subsp. aureus RN4220 Species 0.000 description 2
- 241000187433 Streptomyces clavuligerus Species 0.000 description 2
- 206010044248 Toxic shock syndrome Diseases 0.000 description 2
- 231100000650 Toxic shock syndrome Toxicity 0.000 description 2
- 239000007984 Tris EDTA buffer Substances 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- MZVQCMJNVPIDEA-UHFFFAOYSA-N [CH2]CN(CC)CC Chemical group [CH2]CN(CC)CC MZVQCMJNVPIDEA-UHFFFAOYSA-N 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 229940124350 antibacterial drug Drugs 0.000 description 2
- 239000003782 beta lactam antibiotic agent Substances 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 201000008191 cerebritis Diseases 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 206010014599 encephalitis Diseases 0.000 description 2
- 206010014665 endocarditis Diseases 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000002054 inoculum Substances 0.000 description 2
- 238000005342 ion exchange Methods 0.000 description 2
- 231100000518 lethal Toxicity 0.000 description 2
- 230000001665 lethal effect Effects 0.000 description 2
- 238000007834 ligase chain reaction Methods 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 2
- 238000001471 micro-filtration Methods 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 229940046166 oligodeoxynucleotide Drugs 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 2
- 229920000570 polyether Polymers 0.000 description 2
- 230000001376 precipitating effect Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 230000000644 propagated effect Effects 0.000 description 2
- 238000001742 protein purification Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 239000002336 ribonucleotide Substances 0.000 description 2
- 125000002652 ribonucleotide group Chemical group 0.000 description 2
- FGDZQCVHDSGLHJ-UHFFFAOYSA-M rubidium chloride Chemical compound [Cl-].[Rb+] FGDZQCVHDSGLHJ-UHFFFAOYSA-M 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 238000002741 site-directed mutagenesis Methods 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 238000000527 sonication Methods 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 150000003573 thiols Chemical class 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 238000010361 transduction Methods 0.000 description 2
- 230000026683 transduction Effects 0.000 description 2
- 239000001226 triphosphate Substances 0.000 description 2
- 235000011178 triphosphate Nutrition 0.000 description 2
- 125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 108700026220 vif Genes Proteins 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 239000002132 β-lactam antibiotic Substances 0.000 description 2
- 229940124586 β-lactam antibiotics Drugs 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- WEEMDRWIKYCTQM-UHFFFAOYSA-N 2,6-dimethoxybenzenecarbothioamide Chemical compound COC1=CC=CC(OC)=C1C(N)=S WEEMDRWIKYCTQM-UHFFFAOYSA-N 0.000 description 1
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
- OSJPPGNTCRNQQC-UWTATZPHSA-N 3-phospho-D-glyceric acid Chemical compound OC(=O)[C@H](O)COP(O)(O)=O OSJPPGNTCRNQQC-UWTATZPHSA-N 0.000 description 1
- 241000219195 Arabidopsis thaliana Species 0.000 description 1
- 101100163849 Arabidopsis thaliana ARS1 gene Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 101001011741 Bos taurus Insulin Proteins 0.000 description 1
- 101800001415 Bri23 peptide Proteins 0.000 description 1
- SGHZXLIDFTYFHQ-UHFFFAOYSA-L Brilliant Blue Chemical compound [Na+].[Na+].C=1C=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C(=CC=CC=2)S([O-])(=O)=O)C=CC=1N(CC)CC1=CC=CC(S([O-])(=O)=O)=C1 SGHZXLIDFTYFHQ-UHFFFAOYSA-L 0.000 description 1
- 102400000107 C-terminal peptide Human genes 0.000 description 1
- 101800000655 C-terminal peptide Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 206010007882 Cellulitis Diseases 0.000 description 1
- 102100037633 Centrin-3 Human genes 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 208000008343 Complete atrioventricular septal defect Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 206010011409 Cross infection Diseases 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 108050009160 DNA polymerase 1 Proteins 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 230000007018 DNA scission Effects 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 101001071611 Dictyostelium discoideum Glutathione reductase Proteins 0.000 description 1
- 108090000204 Dipeptidase 1 Proteins 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000186394 Eubacterium Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 206010016936 Folliculitis Diseases 0.000 description 1
- 206010016952 Food poisoning Diseases 0.000 description 1
- 208000019331 Foodborne disease Diseases 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 108700007698 Genetic Terminator Regions Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 108010063907 Glutathione Reductase Proteins 0.000 description 1
- 102000006587 Glutathione peroxidase Human genes 0.000 description 1
- 108700016172 Glutathione peroxidases Proteins 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101000880522 Homo sapiens Centrin-3 Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010021531 Impetigo Diseases 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 102100024319 Intestinal-type alkaline phosphatase Human genes 0.000 description 1
- 101710184243 Intestinal-type alkaline phosphatase Proteins 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 241000186779 Listeria monocytogenes Species 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000186362 Mycobacterium leprae Species 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- 206010028885 Necrotising fasciitis Diseases 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 206010029803 Nosocomial infection Diseases 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010031252 Osteomyelitis Diseases 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108010087702 Penicillinase Proteins 0.000 description 1
- 101100426733 Penicillium chrysogenum TRR1 gene Proteins 0.000 description 1
- 108091093037 Peptide nucleic acid Proteins 0.000 description 1
- 241000186529 Peptoclostridium litorale Species 0.000 description 1
- 108010022181 Phosphopyruvate Hydratase Proteins 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 206010035734 Pneumonia staphylococcal Diseases 0.000 description 1
- 108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 1
- 102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 1
- 239000004721 Polyphenylene oxide Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 108010066717 Q beta Replicase Proteins 0.000 description 1
- 230000002292 Radical scavenging effect Effects 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 108091007187 Reductases Proteins 0.000 description 1
- 241001123227 Saccharomyces pastorianus Species 0.000 description 1
- 101100097319 Schizosaccharomyces pombe (strain 972 / ATCC 24843) ala1 gene Proteins 0.000 description 1
- 239000012506 Sephacryl® Substances 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000191982 Staphylococcus hyicus Species 0.000 description 1
- 241000191980 Staphylococcus intermedius Species 0.000 description 1
- 241000191978 Staphylococcus simulans Species 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 206010042033 Stevens-Johnson syndrome Diseases 0.000 description 1
- 241000187432 Streptomyces coelicolor Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 206010044223 Toxic epidermal necrolysis Diseases 0.000 description 1
- 231100000087 Toxic epidermal necrolysis Toxicity 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 102000004210 Vitamin K Epoxide Reductases Human genes 0.000 description 1
- 108090000779 Vitamin K Epoxide Reductases Proteins 0.000 description 1
- IXKSXJFAGXLQOQ-XISFHERQSA-N WHWLQLKPGQPMY Chemical compound C([C@@H](C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)C1=CNC=N1 IXKSXJFAGXLQOQ-XISFHERQSA-N 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000061 acid fraction Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000005377 adsorption chromatography Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 239000001166 ammonium sulphate Substances 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000010310 bacterial transformation Effects 0.000 description 1
- 238000010296 bead milling Methods 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 102000006635 beta-lactamase Human genes 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- IXIBAKNTJSCKJM-BUBXBXGNSA-N bovine insulin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 IXIBAKNTJSCKJM-BUBXBXGNSA-N 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- MYPYJXKWCTUITO-KIIOPKALSA-N chembl3301825 Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)C(O)[C@H](C)O1 MYPYJXKWCTUITO-KIIOPKALSA-N 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 208000023350 complete atrioventricular canal Diseases 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 108091036078 conserved sequence Proteins 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- 238000011038 discontinuous diafiltration by volume reduction Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 208000009190 disseminated intravascular coagulation Diseases 0.000 description 1
- 150000004662 dithiols Chemical class 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 201000010582 ecthyma Diseases 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 208000010227 enterocolitis Diseases 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000009585 enzyme analysis Methods 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 101150081163 glnA gene Proteins 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 108010064177 glutamine synthetase I Proteins 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 230000002414 glycolytic effect Effects 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 229960004198 guanidine Drugs 0.000 description 1
- 229960000789 guanidine hydrochloride Drugs 0.000 description 1
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 238000012203 high throughput assay Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000004191 hydrophobic interaction chromatography Methods 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000012296 in situ hybridization assay Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 210000004880 lymph fluid Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 108010020410 methionine sulfoxide reductase Proteins 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 229960003085 meticillin Drugs 0.000 description 1
- 230000007269 microbial metabolism Effects 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- ZIUHHBKFKCYYJD-UHFFFAOYSA-N n,n'-methylenebisacrylamide Chemical compound C=CC(=O)NCNC(=O)C=C ZIUHHBKFKCYYJD-UHFFFAOYSA-N 0.000 description 1
- 210000004897 n-terminal region Anatomy 0.000 description 1
- 201000007970 necrotizing fasciitis Diseases 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 244000039328 opportunistic pathogen Species 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229950009506 penicillinase Drugs 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 229940080469 phosphocellulose Drugs 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 229940124606 potential therapeutic agent Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 229950008679 protamine sulfate Drugs 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 102000003336 protein disulfide isomerase activity proteins Human genes 0.000 description 1
- 108040010373 protein disulfide isomerase activity proteins Proteins 0.000 description 1
- 230000012846 protein folding Effects 0.000 description 1
- 230000030788 protein refolding Effects 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000006479 redox reaction Methods 0.000 description 1
- 230000006697 redox regulation Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000000979 retarding effect Effects 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 229940102127 rubidium chloride Drugs 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 239000013605 shuttle vector Substances 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 208000004048 staphylococcal pneumonia Diseases 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 229960002385 streptomycin sulfate Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical compound [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- 101150015970 tetM gene Proteins 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000034005 thiol-disulfide exchange Effects 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 230000002463 transducing effect Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
- C12N9/0036—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on NADH or NADPH (1.6)
Definitions
- This invention relates generally to microbial metabolism and antimicrobial therapeutic agents.
- the invention relates to the bacterial enzyme thioredoxin reductase, to compounds that inhibit this enzyme, and to the use of these compounds as antimicrobial agents, particularly for the therapy of infections caused by Staphylococcus spp.
- Trx reduction by TrxB involves two half- reactions. In the first half-reaction, the FAD prosthetic group of TrxB is reduced by NADPH and electrons are transferred to cysteines present in the active site of TrxB. In the second half-reaction, oxidized Trx is reduced by TrxB.
- the thioredoxin system serves to transfer reducing equivalents for reductive enzymes such as ribonucleotide reductase, methionine sulfoxide reductase and vitamin K epoxide reductase. It also mediates protein folding and exerts specific redox control of some transcription factors to modulate their binding to DNA.
- GSH glutathione
- GSR glutathione reductase
- GSH glutathione peroxidase
- the TrxB component of the thioredoxin system is a FAD-containing enzyme and belongs to a family of pyridine nucleotide-disulfide oxidoreductases.
- the bacterial enzyme obtained from Streptomyces clavuligerus, is a homodimer of 35 kDa subunits and has a native molecular weight of approximately 70 kDa. Aharonowitz et al. (1993) J. Bacteriol. 175:623-629.
- Each subunit of TrxB contains NADPH- and FAD- binding domains and includes an oxidoreductase active dithiol in the conserved sequence -CAT/VC-. Since the cysteine residues of TrxB are relatively inaccessible to the substrate thioredoxin, the enzyme appears to undergo a large conformational change during catalysis.
- TrxBs from different mammalian species including calf (Holmgren, A. (1997) J. Biol. Chem. 252:4600-4606), rat (Luthman et al. (1982) Biochem. 2166628- 6633), and human (Arscott, et al. (1997) Proc. Natl. Acad. Sci. USA 94:3621-3626), have been purified and biochemically characterized.
- the rat liver TrxB has been isolated as a 116 kDa homodimer of 58 kDa subunits, and the mass of human placental TrxB estimated to be 160 kDa by gel-filtration chromatography and 130 kDa (two 65 kDa subunits) by sucrose density gradient centrifugation.
- the size difference between human TrxB and the smaller bacterial TrxBs is primarily due to differences in the dimer-interface domain.
- the redox-active cysteines of human TrxB are located in the FAD domain with a 4-amino acid bridge linking the two cysteines.
- the active-site disulfide of bacterial TrxBs is located within the NADPH domain and a 2-amino acid bridge links the two cysteines.
- the 3D structure of the human TrxB is likely to be more similar to GSR than to the bacterial TrxB.
- primary amino acid sequence alignment of human TrxB with bacterial TrxB sequences reveals just 23-31% identity, whereas alignment of the human TrxB with GSRs of different sources shows 35-44% identity.
- Arscott, et al. (1997) Proc. Natl. Acad. Sci. USA 94:3621-3626.
- the bacterial TrxB Based on the significant differences that exist between the bacterial and the mammalian trxB genes, and the enzymes encoded thereby, the bacterial TrxB provides a potential target for the development of novel antibacterial drugs with a high degree of selectivity.
- Antimicrobial agents commonly used to combat bacterial infections generally interfere with one or more critical steps in the metabolism of the bacterium, resulting in growth inhibition or death of the microbe.
- pathogenic microorganisms including staphylococci, are developing resistance, and in many cases multiple resistances, to existing antimicrobial agents.
- S. aureus is an opportunistic pathogen of increasing medical concern. It can be aggressively invasive, spreading rapidly through soft tissues, directly invading bones and even entering the bloodstream to produce septic shock and disseminated intravascular coagulation.
- Infections caused by staphylococci generally fall within one of two categories: those related to toxins produced by the bacterium exclusively, including gastroenteritis, toxic shock syndrome, scalded skin syndrome, and the like; and those related to direct invasion and systemic spread of the organism, including dermal infections, bone and joint infections, staphylococcal pneumonia and empyema, meningitis, cerebritis, endocarditis, bacteremia, septic shock, and the like.
- TrxB bacterial thioredoxin reductase
- the thioredoxin system provides a significant metabolic function in staphylococci and other Gram-positive bacteria that do not produce glutathione (GSH).
- GSH glutathione
- the thioredoxin system catalyzes a broad range of protein thiol-disulfide exchange reactions, donates hydrogen for ribonucleotide reductase which is an essential enzyme in DNA synthesis, and is involved in redox regulation of numerous enzyme activities.
- Staphylococcal TrxB differs significantly in its function from that of the mammalian enzyme in two important ways. First, it operates in an intracellular environment lacking GSH and GSH-dependent reductases. Second, its subunits are appreciably smaller than the mammalian enzyme and the dimeric enzyme possesses a substrate specificity distinct from its mammalian counterpart. Inhibition of Staphylococcal TrxB activity may cause depletion of reduced low molecular weight thiois, increase protein thiol oxidation, and interfere with DNA synthesis and radical scavenging. Such compromised cells are more likely to succumb to environmental challenges, such as those posed by the host immune system.
- TrxB provides an excellent target for the development of novel antibacterial drugs with a high degree of selectivity.
- antibacterials act by inhibiting TrxB, thereby incapacitating the target bacterium, with few or no side-effects to the eukaryotic host organism.
- inhibitors of TrxB activity are effective antimicrobial agents against Staphylococcus and other microorganisms that depend on TrxB for their redox reactions.
- the invention is directed to an isolated Staphylococcus TrxB polypeptide.
- the invention is directed to an isolated polynucleotide that encodes a Staphylococcus TrxB polypeptide.
- the invention is directed to a recombinant vector comprising the polynucleotide molecule, recombinant host cells transformed with the vector, and methods of producing recombinant polypeptides using the transformed cells.
- the invention is directed to an oligonucleotide probe capable of specifically hybridizing to a nucleic acid molecule encoding a Staphylococcus TrxB.
- the probe includes about 8 to about 50 contiguous nucleotides of the TrxB-encoding polynucleotide.
- antibodies to a Staphylococcus TrxB polypeptide are provided.
- the invention is directed to a method of detecting the presence of Staphylococcus in a test sample suspected of containing a Staphylococcus, comprising:
- the invention is directed to a method of detecting the presence of Staphylococcus in a test sample suspected of containing Stapylococcus, comprising:
- the invention is directed to a method of detecting a Staphylococcus in a test sample suspected of containing a Staphylococcus, comprising:
- the invention is directed to diagnostic kits comprising an oligonucleotide probe as above, a TrxB antibody, or a Staphylococcus TrxB polypeptide, and instructions for conducting the diagnostic test.
- the invention is directed to a method for identifying a compound that modulates Staphylococcus TrxB activity, comprising:
- the invention is directed to compounds identified by this method, compositions comprising the compounds and methods of treating Staphylococcus infections in an infected subject, comprising administering effective antibacterial amounts of the compositions.
- the invention is directed to a method for isolating a TrxB polypeptide from a Staphylococcus cell culture extract, comprising: (a) performing a protein precipitation step with the cell culture extract to yield a first TrxB mixture;
- Figure 1 depicts the nucleotide sequence (SEQ ID NO:1) of the S. aureus trxB open reading frame.
- Figure 2 shows the deduced amino acid sequence (SEQ ID NO:2) of S. aureus TrxB derived from the nucleotide sequence of the open reading frame.
- Figure 3 is a diagram of vector pAUL-A.
- Figure 4 is a diagram of disruption vector pOI7.
- Figures 5A and 5B show the method used to construct the gene replacement vector pOI5.
- Figure 5A shows the construction of plasmid pOI4 used to construct plasmid pOI5, shown in Figure 5B.
- Figure 6 depicts the nucleotide sequence (SEQ ID NO:9) of the S. epidermidis trxB open reading frame.
- FIG. 7 shows an alignment of the TrxB enzymes from S. aureus (designated TrxB_Sa, SEQ ID NO:2) and S. epidermidis (designated TrxB_Se, SEQ ID NO: 10). Colons indicate conservative amino acid substitutions and single dots indicate somewhat conservative substitutions.
- Figure 8 is a flow chart depicting a method for identifying TrxB inhibitors using an insulin turbidity test. Detailed Description
- polynucleotide as used herein means a polymeric form of nucleotides of any length, either ribonucleotides or deoxyribonucleotides. This term refers only to the primary structure of the molecule. Thus, the term includes double- and single-stranded DNA, as well as double- and single-stranded RNA. It also includes modifications, such as by methylation and/or by capping, and unmodified forms of the polynucleotide. "Polypeptide” and “protein” are used interchangeably herein and indicate a molecular chain of amino acids linked through peptide bonds. The terms do not refer to a specific length of the product.
- polypeptides include post-translation modifications of the polypeptide, for example, glycosylations, acetylations, phosphorylations, and the like.
- protein fragments, analogs, muteins, fusion proteins and the like are included within the meaning of polypeptide.
- TrxB polypeptide is meant a polypeptide, whether isolated, recombinant or synthetic, comprising an amino acid sequence identical to that depicted in Figures 2 (SEQ ID NO:2) or 10 (SEQ ID NO: 10), and fragments thereof that include as much of the molecule as necessary for the polypeptide to retain biological activity, e.g., catalytic and/or immunological activity, as well as analogs, mutated or variant proteins, and the like, thereof that retain such activity.
- the polypeptide will include the NADPH- and FAD- binding domains, as well as a redox active site. The NADPH domain is found at residues 146-161 of Figures 2 and 10.
- the polypeptide can include about amino acid residues 1- 277 or more of Figures 2 or 10, or will include the above specified portions, with internal regions deleted, so long as catalytic activity is retained.
- the protein will contain one or more epitopes capable of eliciting a humoral antibody response. Normally, an epitope will include between about 3-20 amino acids, generally about 8-10, and preferably about 15-20 or more amino acids, derived from the TrxB molecule.
- sequence similarity between two amino acid sequences is meant an exact amino acid to amino acid comparison of two or more polypeptides at appropriate portions of the molecule, where identical amino acids are aligned, and where residues are not identical, aligned based on similar chemical and/or physical properties such as charge or hydrophobicity. "Percent similarity” can be determined between the compared polypeptide sequences using techniques well known in the art.
- identity refers to an exact nucleotide to nucleotide or amino acid to amino acid correspondence of two or more polynucleotide or polypeptide 10
- sequence identity is well known in the art and include determining the nucleotide sequence of the mRNA for the gene of interest (usually via a cDNA intermediate) and determining the amino acid sequence encoded thereby, and comparing this to a second amino acid sequence.
- Programs available in the Wisconsin Sequence Analysis Package, Version 8 (available from Genetics Computer Group, Madison, Wl) for example, the GAP program are capable of calculating both the identity between two polynucleotides and the identity and similarity between two polypeptide sequences. Other programs for calculating identity or similarity between sequences are known in the art.
- a polypeptide analog of TrxB will have at least about 50% identity, preferably about 60% identity, more preferably about 75-85% identity, and most preferably about 90-95% or more identity, to the reference TrxB sequence. Further, the polypeptide may have at least about 60% similarity, preferably at least about 75% similarity, more preferably about 85% similarity, and most preferably about 95% or more similarity to the reference sequence. Additionally, a polynucleotide variant will display at least about 50% identity, preferably about 60% identity, more preferably about 75-85% identity, and most preferably about 90-95% or more identity, to the reference trxB nucleotide sequence.
- degenerate variant or “structurally conserved mutation” is intended a polynucleotide containing changes in the nucleic acid sequence thereof, such as insertions, deletions or substitutions, that encodes a polypeptide having the same amino acid sequence as the polypeptide encoded by the polynucleotide from which the degenerate variant is derived.
- Recombinant host cells refer to cells which can be, or have been, used as recipients for recombinant vectors or other transfer DNA, immaterial of the method by which the DNA is introduced into the cell or the subsequent disposition of the cell.
- the terms include the progeny of the original cell which has been transfected. 11
- a "vector” is a replicon in which another polynucleotide segment is attached, such as to bring about the replication and/or expression of the attached segment.
- the term includes expression vectors, cloning vectors, and the like.
- control sequence refers to a polynucleotide sequence which effects the expression of coding sequences to which it is ligated. The nature of such a control sequence differs depending upon the host organism. In prokaryotes, such control sequences generally include a promoter, a ribosomal binding site, and a terminator. In eukaryotes, such control sequences generally include a promoter, a terminator and, in some instances, an enhancer. The term “control sequence” thus is intended to include at a minimum all components necessary for expression, and also may include additional components whose presence is advantageous, for example, leader sequences.
- a "coding sequence” is a polynucleotide sequence that is transcribed into mRNA and/or translated into a polypeptide when placed under the control of appropriate regulatory sequences. The boundaries of the coding sequence are determined by a translation start codon at the 5'-terminus and a translation stop codon at the 3'-terminus.
- a coding sequence can include, but is not limited to, mRNA, cDNA, and recombinant polynucleotide sequences. Mutants or analogs may be prepared by the deletion of a portion of the coding sequence, by insertion of a sequence, and/or by substitution of one or more nucleotides within the sequence.
- operably linked refers to a situation wherein the components described are in a relationship permitting them to function in their intended manner.
- a control sequence "operably linked" to a coding sequence is ligated in such a manner that expression of the coding sequence is achieved under conditions compatible with the control sequences.
- a coding sequence may be operably linked to control sequences that direct the transcription of the polynucleotide whereby said polynucleotide is expressed in a host cell. 12
- Transformation refers to the insertion of an exogenous polynucleotide into a host cell, irrespective of the method used for the insertion, or the molecular form of the polynucleotide that is inserted. For example, injection, direct uptake, transduction, and f-mating are included. Furthermore, the insertion of a polynucleotide per se and the insertion of a plasmid or vector comprised of the exogenous polynucleotide, are also included.
- the exogenous polynucleotide may be directly transcribed and translated by the cell, maintained as a nonintegrated vector, for example, a plasmid, or alternatively, may be stably integrated into the host genome.
- probe denotes a defined nucleic acid segment which can be used to identify a specific polynucleotide present in samples bearing the complementary sequence.
- a probe will generally include about 8 to about 75 contiguous nucleic acids of the reference polynucleotide, generally about 12 to about 50 contiguous nucleic acids, and preferably about 15-18 to about 30 contiguous nucleic acids of the reference sequence.
- isolated when referring to a polynucleotide or a polypeptide, intends that the indicated molecule is present in the substantial absence of other similar biological macromolecules of the same type.
- isolated as used herein means that at least 75 wt.%, more preferably at least 85 wt.%, more preferably still at least 95 wt.%, and most preferably at least 98 wt.% of a composition is the isolated polynucleotide or polypeptide.
- isolated polynucleotide that encodes a particular polypeptide refers to a polynucleotide that is substantially free of other nucleic acid molecules that do not encode the subject polypeptide; however, the molecule may include conservative mutations as defined herein. Thus, an isolated polynucleotide would not be a polynucleotide as it exists on the chromosome.
- test sample refers to a component of an individual's body which is the source of an analyte, such as antibodies or antigens of interest.
- test samples include biological samples which can be tested by the methods of the present invention described herein and include human and animal body fluids such 13
- the present invention is based on the identification of novel Staphylococcal TrxB polypeptides, including S. aureus TrxB (also termed TrxB_Sa herein) and S. epidermidis TrxB (also termed TrxB_Se herein), as well as polynucleotides encoding the TrxBs, and methods of making the TrxBs.
- the invention includes not only the enzyme but also methods for screening compounds for pharmacological activity using the enzyme, cells expressing the enzyme, antibodies to the enzyme and the use of polynucleotides and antibodies to diagnose the presence of Staphylococcus in a test sample.
- the inventors herein have identified new TrxB enzymes in S. aureus and S. epidermidis.
- the native enzyme has a molecular mass (M r ) of approximately 70 kDa, as determined by gel filtration chromatography.
- the enzyme exists as a homodimer having a subunit M r of about 35 kDa, as determined by SDS 14
- the predicted value of the Staphylococcal TrxB subunit molecular mass, based on the primary amino acid sequence is 33.518, and the calculated isoelectric point (PI) is 5.39.
- the gene encoding the S. aureus TrxB enzyme has been cloned and the ORF coding for the TrxB protein is shown in Figure 1.
- the gene encoding the S. epidermidis TrxB enzyme has been identified and the nucleotide and amino acid sequences are shown in Figures 6 and 7, respectively.
- the enzyme can be isolated directly from bacteria as follows. Bacteria are cultured in a suitable culture medium, such as trypticase soy broth (TSB). The bacteria are then removed from the culture medium using standard techniques known in the art, such as by centrifugation or microfiltration or a combination of the two. For example, microfiltration using an appropriate filter will suffice to remove unwanted cellular debris.
- TTB trypticase soy broth
- Bacteria thus obtained are prepared to release the contents of the cytoplasm.
- Bacterial cells may be broken using methods and/or reagents known in the art that do not adversely affect the structure and/or the activity of the TrxB, e.g., exposure to freeze-thaw cycles, exposure to an ultrasonic disintegrator, homogenization, bead milling, chemical or enzymatic cell lysis, and the like.
- cells are incubated in a buffer containing lysostaphin, a lytic agent for S. aureus, and then centrifuged to remove insoluble cellular debris.
- the bacterial cell extract thus prepared can be further processed to separate the protein from the cellular debris, and provide an initial stage of purification and volume reduction.
- the extract obtained from the previous step may be processed by a primary separation procedure such as ultrafiltration, i.e., passage through a filter having an appropriate molecular weight cut-off, to concentrate the sample by reducing the water and salt content.
- the extract may be precipitated by neutral salts such as ammonium sulphate, organic solvents such as ethanol, or other agents for recovering and purifying the protein.
- Staphylococcus TrxB is precipitated from the extract by adding ammonium sulfate to the extract to approximately 30% to 50% saturation, preferably 40% saturation.
- the supernatant of the same is collected by, e.g., centrifugation, and the ammonium sulfate is adjusted to about 70% to 90%, preferably 80% saturation.
- the treated precipitate thus obtained is collected and used in further purification steps.
- a number of protein purification operations may be used to further purify the Staphylococcus TrxB including adsorption chromatography, ion-exchange chromatography, hydrophobic interaction chromatography, affinity chromatography, chromatofocussing, gel-filtration, reversed-phase liquid chromatography, phosphocellulose chromatography, hydroxyapatite chromatography or lectin chromatography, any combination of such techniques. Protein refolding steps can be used, as necessary, in completing configuration of the protein. Finally, high performance liquid chromatography (HPLC) can be employed for final purification steps. For example, the fraction precipitating between 40-80% ammonium sulfate saturation can be applied to a gel-filtration matrix for size separation.
- HPLC high performance liquid chromatography
- Useful matrices for size separation include any of several known in the art such as, without limitation, those made of dextran, dextran/bisacrylamide, polyacrylamide, agarose, cross-linked agarose, agarose/polyacrylamide, and cross-linked polyethers.
- Particularly preferred matrices are those which allow fractionation of molecules in the size range of about 10 4 to 10 6 , such as Sephacryl S-300, Sepharose 6B, Sepharose CL-6B, Ultragel AcA44, Ultragel AcA34, Ultragel A6, and the like.
- ion-exchangers are anion-exchangers, well known in the art. Particularly preferred herein are relatively weak anion-exchangers, such as those including aminoethyl (AE) or diethylaminoethyl (DEAE) functionalities.
- useful matrix materials include but are not limited to, cellulose matrices, such as fibrous, microgranular and beaded matrices; agarose, dextran, polyacrylate, polyvinyl, 16
- a representative anion- exchanger for use herein is DEAE-Sepharose.
- TrxB activity can be monitored during purification using standard TrxB assays.
- the presence of TrxB can be assayed spectrophotometrically by monitoring the NADPH- and TrxB disulfide-dependent reduction of a disulfide- containing substrate.
- One assay method monitors the reduction of 5,5'-dithio-6/s-2- nitrobenzoic acid (DTNB) at 412 nm. See, e.g., Ellman (1959) Arch. Biochem. Biophys. 82:70-77.
- a particularly preferred assay uses insulin as the disulfide- containing substrate.
- the presence of free sulfhydryl (SH) groups in insulin are measured at 650 nm as an indication of TrxB activity.
- SH free sulfhydryl
- TrxB specifically reduces thioredoxin (T-S 2 ) to T-(SH) 2 using NADPH.
- T-S 2 thioredoxin
- the formed T-(SH) 2 in turn reduces native insulin.
- Insulin can be replaced by any of several low molecular weight disulfide compounds in the assay, such as cystine, and TrxB activity is monitored spectrophotometrically following the oxidation of NADPH.
- amino acid sequences of the proteins can be determined, e.g., by repetitive cycles of Edman degradation, followed by amino acid analysis by HPLC. Other methods of amino acid sequencing are also known in the art. Based on knowledge of the amino acid sequence, DNA encoding the enzyme can be derived from genomic or cDNA, prepared by synthesis, or by a combination of techniques. The DNA can then be used to express the TrxB, or as a template for the preparation of RNA, using methods well known in the art (see, Sambrook et al., supra).
- DNA encoding the Staphylococcus TrxB may be obtained from an appropriate DNA library, e.g., an S. aureus or S. epidermidis genomic DNA library.
- DNA libraries may be probed using the procedure described by Grunstein et al. (1975) Proc. Natl. Acad. Sci. USA 73:3961. Briefly, the DNA to be probed is 17
- a buffer which contains 0-50% formamide, 0.75 M NaCI, 75 mM Na citrate, 0.02% (w/v) each of bovine serum albumin (BSA), polyvinyl pyrollidone and Ficoll®, 50 mM Na phosphate (pH 6.5), 0.1% sodium dodecyl sulfate (SDS) and 100 ⁇ g/ml carrier denatured DNA.
- BSA bovine serum albumin
- SDS sodium dodecyl sulfate
- Oligomeric probes which require lower stringency conditions are generally used with low percentages of formamide, lower temperatures, and longer hybridization times.
- Probes containing more than 30 or 40 nucleotides such as those derived from cDNA or genomic sequences generally employ higher temperatures, for example, about 40°C to 42°C, and a high percentage, for example, 50%, formamide.
- a 32 P-labelled oligonucleotide probe is added to the buffer, and the filters are incubated in this mixture under hybridization conditions. After washing, the treated filters are subjected to autoradiography to show the location of the hybridized probe. DNA in corresponding locations on the original agar plates is used as the source of the desired DNA.
- Synthetic oligonucleotides may be prepared using an automated oligonucleotide synthesizer such as that described by Warner (1984) DNA 3:401. If desired, the synthetic strands may be labeled with 32 P by treatment with polynucleotide kinase in the presence of 32 P-ATP, using standard conditions for the reaction. DNA sequences including those isolated from genomic or cDNA libraries, may be modified by known methods which include site-directed mutagenesis as described by Zoller (1982) Nucleic Acids Res. 10:6487.
- the DNA to be modified is packaged into phage as a single stranded sequence, and converted to a double stranded DNA with DNA polymerase using, as a primer, a synthetic oligonucleotide complementary to the portion of the DNA to be modified, and having the desired modification included in its own sequence.
- Cultures of the transformed bacteria, which contain replications of each strand of the phage, are plated in agar to obtain plaques. Theoretically, 50% of the new plaques contain phage having the 18
- Replicates of the plaques are hybridized to labeled synthetic probe at temperatures and conditions suitable for hybridization with the correct strand, but not with the unmodified sequence.
- the sequences which have been identified by hybridization are recovered and cloned.
- the DNA may then be incorporated into a cloning or expression vector for replication in a suitable host cell.
- Vector construction employs methods known in the art. Generally, site-specific DNA cleavage is performed by treating with suitable restriction enzymes under conditions which generally are specified by the manufacturer of these commercially available enzymes. Usually, about 1 microgram ( ⁇ g) of plasmid or DNA sequence is cleaved by 1-10 units of enzyme in about 20 ⁇ l of buffer solution by incubation at 37°C for 1 to 2 hours. After incubation with the restriction enzyme, protein is removed by phenol/chloroform extraction and the DNA recovered by precipitation with ethanol. The cleaved fragments may be separated using polyacrylamide or agarose gel electrophoresis methods, according to methods known by those of skill in the art.
- Sticky end cleavage fragments may be blunt ended using E. coli DNA polymerase 1 (Klenow) in the presence of the appropriate deoxynucleotide triphosphates (dNTPs) present in the mixture. Treatment with S1 nuclease also may be used, resulting in the hydrolysis of any single stranded DNA portions.
- E. coli DNA polymerase 1 Klenow
- dNTPs deoxynucleotide triphosphates
- Ligations are performed using standard buffer and temperature conditions using T4 DNA ligase and ATP. Sticky-end ligations require less ATP and less ligase than blunt-end ligations.
- the vector fragment often is treated with bacterial alkaline phosphatase (BAP) or calf intestinal alkaline phosphatase to remove the 5'-phosphate and thus prevent religation of the vector.
- BAP bacterial alkaline phosphatase
- calf intestinal alkaline phosphatase calf intestinal alkaline phosphatase
- restriction enzyme digestion of unwanted fragments can be used to prevent ligation.
- ligation mixtures are transformed into a suitable host, and successful transformants selected by antibiotic resistance or other markers. Plasmids from the transformants can then be prepared according to the 19
- Host cells are genetically engineered (transduced, transformed, or transfected) with the vectors of this invention which may be a cloning vector or an expression vector.
- the vector may be in the form of a plasmid, a viral particle, a phage, etc.
- the engineered host cells can be cultured in conventional nutrient media modified as appropriate for activating promoters, selecting transformants or amplifying the TrxB-encoding polynucleotide.
- the culture conditions such as temperature, pH and the like, are those previously used with the host cell selected for expression, and will be apparent to those of skill in the art.
- prokaryotic and eukaryotic host cells may be used for expression of desired coding sequences when appropriate control sequences that are compatible with the designated host are used.
- E. coli is frequently used.
- Expression control sequences for prokaryotes include promoters, optionally containing operator portions, and ribosome binding sites.
- Transfer vectors compatible with prokaryotic hosts are commonly derived from the plasmid pBR322 that contains operons conferring ampicillin and tetracycline resistance, and the various pUC vectors, that also contain sequences conferring antibiotic resistance markers. These markers may be used to obtain successful transformants by selection.
- prokaryotic control sequences include the ⁇ -lactamase (penicillinase), lactose promoter system (Chang et al. (1977) Nature 198:1056), the tryptophan promoter system (reported by Goeddel et al. (1980) Nucleic Acid Res. 8:4057) and the lambda-derived PI promoter and N gene ribosome binding site 20
- Eukaryotic hosts include yeast and mammalian cells in culture systems. Saccharomyces cerevisiae and S. carlsbergensis are commonly used yeast hosts, and are convenient fungal hosts.
- Yeast-compatible vectors carry markers that permit selection of successful transformants by conferring protrophy to auxotrophic mutants or resistance to heavy metals on wild-type strains.
- Yeast compatible vectors may employ the 2-micron origin of replication (Broach et al. (1983) Meth. Enzymol. 101 :307), the combination of CEN3 and ARS1 or other means for assuring replication, such as sequences that will result in incorporation of an appropriate fragment into the host cell genome.
- Control sequences for yeast vectors are known in the art and include promoters for the synthesis of glycolytic enzymes, including the promoter for 3-phosphoglycerate kinase. See, for example, Hess et al. (1968) J. Adv. Enzyme Reg. 7:149, Holland et al. (1978) Biochemistry 17:4900, and Hitzeman (1980) J. Biol. Chem. 255:2073. Terminators also may be included, such as those derived from the enolase gene as reported by Holland (1981) J. Biol. Chem. 256:1385.
- particularly useful control systems are those that comprise the glyceraldehyde-3-phosphate dehydrogenase (GAPDH) promoter or alcohol dehydrogenase (ADH) regulatable promoter, terminators also derived from GAPDH, and, if secretion is desired, leader sequences from yeast alpha factor.
- GPDH glyceraldehyde-3-phosphate dehydrogenase
- ADH alcohol dehydrogenase
- terminators also derived from GAPDH
- leader sequences from yeast alpha factor
- the transcriptional regulatory region and the transcriptional initiation region which are operably linked may be such that they are not naturally associated in the wild-type organism.
- Mammalian cell lines available as hosts for expression are known in the art and include many immortalized cell lines which are available from the American Type Culture Collection. These include HeLa cells, Chinese hamster ovary (CHO) cells, baby hamster kidney (BHK) cells, and others. Suitable promoters for 21
- mammalian cells also are known in the art and include viral promoters such as that from Simian Virus 40 (SV40), Rous sarcoma virus (RSV), adenovirus (ADV), bovine papilloma virus (BPV), cytomegalovirus (CMV).
- SV40 Simian Virus 40
- RSV Rous sarcoma virus
- ADV adenovirus
- BPV bovine papilloma virus
- CMV cytomegalovirus
- Mammalian cells also may require terminator sequences and poly A addition sequences; enhancer sequences which increase expression also may be included, and sequences which cause amplification of the gene also may be desirable. These sequences are known in the art.
- Vectors suitable for replication in mammalian cells may include viral replicons, or sequences which insure integration of the appropriate sequences encoding the Staphylococcus TrxB into the host genome.
- eukaryotic systems are also known, as are methods for introducing polynucleotides into such systems, such as into amphibian cells, using known methods, and insect cells using methods described in Summers and Smith (1987), Texas Agricultural Experiment Station Bulletin No. 1555, and the like.
- Transformation may be by any known method for introducing polynucleotides into a host cell, including packaging the polynucleotide in a virus and transducing a host cell with the virus, by direct uptake of the polynucleotide by the host cell, and the like.
- the transformation procedures selected depend upon the host to be transformed.
- Bacterial transformation by direct uptake generally employs treatment with calcium or rubidium chloride.
- Yeast transformation by direct uptake may be conducted using the calcium phosphate precipitation method of Graham et al. (1978) Virology 52:526, or modification thereof.
- TrxB expression of active TrxB can be assayed spectrophotometrically, as described above, by monitoring the NADPH- and TrxB disulfide-dependent reduction of a disulfide-containing substrate.
- Particularly useful substrates include DTNB and insulin. See, e.g., Ellman (1959) Arch. Biochem. Biophys. 82:70-77; and A. Holmgren and M. Bjomstedt, (1995) Methods in Enzymology 252:199-208.
- expression of TrxB can be monitored using an ELISA assay and antibodies prepared to the isolated TrxB enzyme. The enzyme is recovered and 22
- the Staphylococcus TrxB polypeptide or fragments thereof may also be synthesized by conventional techniques known in the art, for example, by chemical synthesis such as solid-phase peptide synthesis. In general, these methods employ either solid- or solution- phase synthesis methods, well known in the art. See, e.g., J. M. Stewart and J. D. Young, Solid Phase Peptide Synthesis, 2nd Ed., Pierce Chemical Co., Rockford, IL (1984) and G. Barany and R. B. Merrifield, The Peptides: Analysis, Synthesis, Biology, editors E. Gross and J. Meienhofer, Vol. 2, Academic Press, New York, (1980), pp. 3-254, for solid phase peptide synthesis techniques; and M.
- the enzyme may be used to identify compounds that modulate Staphylococcus TrxB activity.
- enzyme activity and the effects of compounds on enzyme activity can be assayed spectrophotometrically by monitoring the NADPH- and TrxB disulfide-dependent reduction of 5,5'-dithio- ⁇ b/s-2-nitrobenzoic acid (DTNB) at 412 nm, or by measuring the presence of free SH groups of insulin at 650 nm.
- DTNB 5,5'-dithio- ⁇ b/s-2-nitrobenzoic acid
- Purification or expression of Staphylococcus TrxB, and screening for compounds that inhibit the enzyme activity provides a method for rapid selection of compounds with enzyme-inhibiting activity.
- Staphylococcus TrxB Compounds that inhibit Staphylococcus TrxB are considered potential therapeutic agents for use in treating several disorders caused by staphylococcal bacteria, including without limitation those caused by S. aureus, S. epidermidis, S. albus, S. hyicus, S. hyos, S. intermedius, S. simulans, and the like. These bacteria cause infection in man and other nonhuman primates, as well as in domestic animals, such as dogs and cats, and in farm animals, including horses, pigs, sheep, goats and cows. These agents are therefore useful in preventing or retarding 23
- TrxB inhibitors are useful therapeutic agents
- diseases for which TrxB inhibitors are useful therapeutic agents include any of the several infections caused by staphylococci including, but not limited to, gastroenteritis, enterocolitis, toxic shock syndrome, scalded skin syndrome, dermal infections, cellulitis, toxic epidermal necrolysis, ecthyma, necrotizing fasciitis, folliculitis, furuncles, carbuncles, impetigo, bone and joint infections, osteomyelitis, pneumonia and empyema, meningitis, cerebritis, endocarditis, bacteremia, septic shock, septicemia, food poisoning, enteritis, and the like.
- inhibitory compounds of the present invention can be formulated into pharmaceutical compositions in a variety of dosage forms such as, but not limited to, liquid solutions or suspensions, tablets, pills, powders, ointments suppositories, polymeric microcapsules or microvesicles, liposomes, and injectable or infusible solutions.
- dosage forms such as, but not limited to, liquid solutions or suspensions, tablets, pills, powders, ointments suppositories, polymeric microcapsules or microvesicles, liposomes, and injectable or infusible solutions.
- the preferred form depends upon the mode of administration and the particular microorganism and disease targeted.
- compositions also preferably include pharmaceutically acceptable vehicles, carriers or adjuvants, well known in the art, such as human serum albumin, ion exchangers, alumina, lecithin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, and salts or electrolytes such as protamine sulfate.
- Suitable vehicles are, for example, water, saline, dextrose, glycerol, ethanol, or the like, and combinations thereof.
- Actual methods of preparing such compositions are known, or will be apparent, to those skilled in the art. See, e.g., Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, Pennsylvania, 18th edition, 1990.
- compositions can be administered using conventional modes of delivery including, but not limited to, intramuscular, intravenous, intraperitoneal, oral, intralymphatic, or subcutaneous administration.
- Local administration to a tissue in question, or to a site of infection, e.g., direct injection into an infected joint, will also find use with the present invention.
- Therapeutically effective doses will be easily determined by one of skill in the art and will depend on the severity and course of the disease, the patient's health and response to treatment, and the judgment of the treating physician.
- the Staphylococcus TrxB polypeptide can be used to prepare polyclonal or monoclonal antibodies using techniques that are well known in the art. If polyclonal antibodies are desired, a selected mammal, (e.g., mouse, rabbit, goat, horse, etc.) is immunized with a TrxB polypeptide and serum from the immunized animal is collected and treated according to known procedures. See, e.g., Jurgens et al. (1985) J. Chrom. 348:363-370. If serum containing polyclonal antibodies is used, the polyclonal antibodies can be purified by immunoaffinity chromatography, using known procedures.
- Monoclonal antibodies to the TrxB polypeptides can also be readily produced by one skilled in the art.
- the general methodology for making monoclonal antibodies using hybridoma technology is well known.
- Immortal antibody-producing cell lines can be created by cell fusion, as well as by other techniques, such as direct transformation of B-lymphocytes with oncogenic DNA, or transfection with Epstein-Barr virus. See, e.g., M. Schreier er al., Hybridoma Techniques (1980); Hammerling et al., Monoclonal Antibodies and T-cell Hybridomas (1981); Kennett et al., Monoclonal Antibodies (1980); U.S. Patent Nos.
- Panels of monoclonal antibodies produced against the TrxB polypeptides can be screened for various properties; e.g., for isotype, epitope, affinity, etc. Monoclonal antibodies are useful in purification, using immunoaffinity techniques, of the TrxB polypeptides.
- Monoclonal and polyclonal antibodies that display specificity and selectivity for the enzyme can be labeled with a detectable moiety, e.g., a fluorescent moiety, and used in in vitro, or in situ immunofluorescent assays, or the like.
- the antibodies can be used to identify Staphylococcus for immunodiagnostic purposes.
- DNA encoding the Staphylococcus TrxBs, or RNA derived therefrom, can be used to design oligonucleotide probes for Staphylococcus present 25
- probe refers to a structure comprised of a polynucleotide, as defined above, which contains a nucleic acid sequence complementary to a nucleic acid sequence present in a target polynucleotide.
- the polynucleotide regions of probes may be composed of DNA, and/or RNA, and/or synthetic nucleotide analogs such as morpholino compounds and peptide nucleic acid (“PNA”) analogs.
- PNA peptide nucleic acid
- oligomers of approximately eight or more nucleotides can be prepared, either by excision or synthetically, which hybridize with the TrxB-encoding polynucleotide. Such oligomers are useful, for example, for detecting the presence of bacteria in diseased individuals.
- the natural or derived probes for trxB polynucleotides are a length that allows the detection of unique sequences by hybridization. While 6-8 nucleotides may be a workable length, sequences of 10-12 nucleotides are preferred, and those of about 18-20 nucleotides, or more, most preferred. These probes can be prepared using routine, standard methods including automated oligonucleotide synthetic methods.
- the test sample to be analyzed such as blood or serum
- the test sample to be analyzed may be treated such as to extract a nucleic acid fraction thereof.
- the resulting nucleic acid from the sample may be subjected to gel electrophoresis or other size separation techniques, or the nucleic acid sample may be dot-blotted without size separation.
- the sample is then exposed to an oligonucleotide probe that has been detectably labeled.
- Suitable labels and methods for attaching labels to probes are known in the art, and include but are not limited to radioactive labels incorporated by nick translation or kinasing, biotin, fluorescent and chemiluminescent probes, enzymes which catalyze the production of a detectable product such as horseradish peroxidase, alkaline phosphatase, ⁇ -galactosidase, and the like.
- the nucleic acids extracted from the 26 include but are not limited to radioactive labels incorporated by nick translation or kinasing, biotin, fluorescent and chemiluminescent probes, enzymes which catalyze the production of a detectable product such as horseradish peroxidase, alkaline phosphatase, ⁇ -galactosidase, and the like.
- sample are then treated with the labeled probe under conditions of suitable hybridization stringency.
- the stringency of hybridization is determined by a number of factors during the washing procedure, including temperature, ionic strength, length of time and concentration of formamide. Sambrook et al., supra. Hybridization can be carried out by a number of techniques. Amplification of the sample nucleic acid, if required, can be performed, for example, by ligase chain reaction (LCR), polymerase chain reaction (PCR), Q-beta replicase, NASBA, or other techniques well known in the art. The amplified nucleic acids then may be detected using a hybridization assay such as those known in the art.
- LCR ligase chain reaction
- PCR polymerase chain reaction
- NASBA Q-beta replicase
- TrxB antibodies thereto, as well as polynucleotides encoding TrxB or portions thereof, can be provided in diagnostic kits.
- oligomer probes capable of specifically hybridizing to a polynucleotide encoding a TrxB can be packaged in diagnostic kits which include the probe nucleic acid sequence which may be labelled.
- the probe may be provided unlabelled and the ingredients for labelling can be included with the kit.
- the kit also may contain other suitably packaged reagents and materials needed or desirable for the particular hybridization protocol, for example, standards as well as instructions for performing the assay.
- kits can include reagents for detecting of the presence and/or amount of Staphylococcus TrxB in a test sample, as well as for detecting the presence of Staphylococcus.
- reagents can comprise, e.g., an antibody capable of specifically binding to the TrxB polypeptide.
- kits containing a Staphylococcus TrxB polypeptide in a suitable container are provided for screening compounds for TrxB-modulating activity or for screening test samples for the presence of a TrxB antibody.
- reagents employed in the above kits can be provided in one or more containers such as vials or bottles, with each container containing a separate reagent such as a monoclonal antibody, or a cocktail of monoclonal antibodies, or a polypeptide (either recombinant or synthetic) employed in the assay.
- Other components such as 27
- test kits may include buffers, controls, and the like, known to those of ordinary skill in art, known to those of ordinary skill in art, may be included in such test kits.
- the kits will also include instructions for the use thereof.
- Example 1 Identification of a Thioredoxin Reductase from S. aureus
- S. aureus extracts were analyzed for thioredoxin reductase (TrxB) activity on oxidized thioredoxin in a NADPH-dependent reaction specific for the reduction of insulin as the protein disulfide substrate. 10 ml of an overnight culture of S.
- aureus RN8325-4 obtained from Richard Novick at New York University School of Medicine
- TTB tryptic soy broth
- TSB medium Difco Laboratories, Detroit, Ml
- Cells were harvested by centrifugation (8000 x g, 15 min), resuspended in 50 mM Tris HCI buffer (20 ml) containing 1 mM EDTA and disrupted by sonication. The homogenized suspension was cleared from insoluble cellular debris by centrifugation and saved.
- the supernatant was brought to a final concentration of 1% streptomycin sulfate, stirred for 30 min and the nucleic acid precipitate removed by centrifugation. Ammonium sulfate was added to the clear liquid and the fraction that precipitated between 40-80% ammonium sulfate saturation was collected by centrifugation, dissolved in a minimal volume of buffer and chromatographed on a AcA44 gel-filtration size column.
- TrxB activity Fractions exhibiting TrxB activity were separated from those containing the Trx activity and served as the high and low molecular weight protein components.
- a typical assay (Table 1) consisted of a 40 ⁇ l fraction of the high molecular weight component from the AcA44 gel-filtration column to which was added 40 ⁇ l of a solution containing HEPES buffer pH 7.6, 0.26 M; EDTA 0.01 M; NADPH 2.0 mM; insulin, 1.03 mM.
- the reaction was initiated by adding a 20 ⁇ l fraction of the low molecular weight Trx component eluted from the same gel-filtration column and the mixture was incubated for 20 min at 37°C. The reaction was stopped with 500 ⁇ l of a solution containing 0.4 mg DTNB/ml and 6 M Guanidine HCI in 0.2 M Tris HCI, pH 8.0, and the absorbance A 412 read.
- Table 1 shows the ability of the S. aureus thioredoxin system to reduce insulin disulfides in the presence of NADPH.
- TrxB was purified from cell extracts of S. aureus by following the NADPH-dependent reduction of DTNB.
- the cell pellet was resuspended in a minimum of TE buffer (50 mM Tris HCI, pH 8.0, 1 mM EDTA) containing phenylmethylsulphonyl fluoride (PMSF) (1 mM) and lysostaphin (0.5 mg), incubated at 4°C, stirred for 30 min, disrupted further by sonication and then centrifuged (15,000 x g, 20 min) to remove insoluble cellular debris. Streptomycin was added to a final concentration of 1%, stirred for 30 min at 4°C and the nucleic acid precipitate removed by centrifugation.
- TE buffer 50 mM Tris HCI, pH 8.0, 1 mM EDTA
- PMSF phenylmethylsulphonyl fluoride
- lysostaphin 0.5 mg
- the clear supernatant was brought to 40% saturation with ammonium sulfate, stirred to 15 min, and centrifuged (15,000 x g, 10 min). The resulting supernatant was adjusted to 80% saturation with ammonium sulfate and the precipitate collected by centrifugation. The fraction precipitating between 40-80% ammonium sulfate saturation was dissolved in a small volume of buffer and applied to an AcA44 gel-filtration column for size separation chromatography.
- Fractions containing the TrxB activity were easily separated from those containing the Trx activity. Fractions exhibiting TrxB and Trx activity were pooled, dialyzed and applied to a DEAE-Sepharose ion exchange column. The column was washed with the loading buffer (TE) and eluted with a linear gradient of NaCI (0.0- 0.5 M) in TE buffer. Fractions containing the TrxB activity were collected and used for further reactions. The purity of fractions showing TrxB activity was determined by SDS-PAGE. The molecular weight of the monomer was determined to be approximately 35 kDa using SDS-PAGE. 30
- trxB_Sa The gene encoding S. aureus TrxB (trxB_Sa) was isolated and sequenced as described below. Generally, the gene was identified by PCR using degenerate primers, shown in Table 2A, based on the conserved N-terminal and C-terminal sequences, shown in Table 2B, of known bacterial thioredoxin reductases. See, e.g., Russell et al. (1988) J. Biol. Chem. 263:9015-9019, for the sequence of E. coli
- TrxB Cohen et al. (1993) J. Bactehol. 175:5159-5167, for the sequence of S. clavuligerus TrxB; Cohen et al. (1994) J. Bactehol. 176:973-984, for the sequence of Penicillium chrysogenum TrxB; Dai ef al. (1996) J. Mol. Biol. 264:1044-1057, for the sequence of Arabidopsis thaliana TrxB; Lubbers et al. (1993) Eur. J. Biochem.
- N-terminal peptide TEEVENFPG (SEQ ID NO:5)
- C-terminal peptide GIFAAGD (SEQ ID NO:6)
- oligodeoxynucleotides which were designed to encode the N- terminal and C-terminal trxB sequences were used as primers for PCR of S. aureus genomic DNA.
- the PCR reaction contained the following: 100 ng genomic DNA, 50 ⁇ m each of
- SEQ ID NO:4 SEQ ID NO:4; MgCI 2 (1.5 mM); bovine serum albumin (BSA) (5 ⁇ g); deoxynucleotide triphosphates (dNTPs) (0.2 mM each); and 1 x PCR buffer (Fermentas, MBI).
- BSA bovine serum albumin
- dNTPs deoxynucleotide triphosphates
- the resulting 700 bp PCR product was cloned directly using an AT cloning kit (Promega) and sequenced using universal "forward" and "reverse" primers which are homologous to the flanking region of the multiple cloning site within the plasmid pGEMT (the AT cloning vector (Promega)).
- the cloning vector including the 700 bp PCR product was termed pOI1.
- the fragment from above was labeled with digoxygenin and used to probe Southern blots of S. aureus genomic DNA digested with various restriction enzymes.
- a single 2.8 kb Xbal fragment that hybridized to the probe under stringent conditions (50% formamide, 42 C) was subcloned into plasmid pUC18 to form pOI2 and sequenced.
- Initial sequencing primers were designed to prime within the sequence of the PCR fragment described above and to sequence into the flanking regions.
- New primers were designed within the new sequences and the nucleotide sequence of the entire gene was thus determined stepwise. All of the sequences were confirmed by sequencing both the coding and non-coding strands.
- S. aureus trxB gene and the deduced amino acid sequence are shown in Figure 1 (SEQ ID NO:1) and Figure 2 (SEQ ID NO:2), respectively.
- CLUSTALW Program Thimpson ef al. (1994) Nucl. Acid Res. 22:4673-4680
- the S. aureus TrxB amino acid sequence was compared to other bacterial TrxBs. All parameters used were the standard default parameters recommended by CLUSTALW (see, web site http://www2.ebi.ac.uk/clustalw).
- the open reading frame encoding S. aureus TrxB is amplified by the PCR reaction using the N-terminal primer 5'-
- GGGAATTCCATATGACTGAAATAGATTTTGAT-3 * (SEQ ID NO:7) and the C- terminal PCR primer 5'-CCCAAGCTTTTAAGCTTGATCGTTTAA-3' (SEQ ID NO:8).
- the resulting fragment is digested with ⁇ /del and HindWl, purified and ligated with vector pET14b (Novagen, Inc. Madison Wl) that is digested with the same two enzymes and purified similarly to produce plasmid pTRSA.
- coli BL21 (DE3) cells harboring pTRSA is washed twice in 10 ml of TB medium and used as an inoculum for 1 liter of the same medium containing ampicillin (400 mg/mL).
- the resulting culture is incubated at 37°C until it reaches mid-stationary phase (A 600 ⁇ 1.2), induced to express recombinant TrxB (rTrxB) by the addition of IPTG (to 1 mM) and then incubated for an additional 3 hours at 37°C.
- the cells are harvested and the recombinant enzyme is purified as described in Example 2 for native TrxB, except that lysozyme (2 mg/mL) is used in place of 33
- lysostaphin to assist in disrupting the cells.
- the purity of the resulting recombinant enzyme is measured by SDS-PAGE and staining with Coomasie brilliant blue.
- the integrated plasmid can be stably maintained employing selection for the genetic marker, erythromycin resistance, carried on the plasmid sequence.
- homologous chromosomal fragment represents a segment internal to a gene
- a single recombinational crossover of the plasmid into the chromosome will cause disruption of the gene and result in the inactivation of the corresponding polypeptide.
- the homologous chromosomal fragment contains a deletion internal to a gene
- a single recombinational crossover of the plasmid into the chromosome generates a tandem arrangement of wild-type and mutant genes separated by the plasmid sequence; a second recombination event results in loss of one of the copies and the intervening plasmid sequence which, if of the wild-type copy, leads to gene replacement and inactivation of the corresponding polypeptide.
- the replacement plasmid was made as follows (see Figures 5A and 5B).
- the 3.1 kb Pvu ⁇ -Hind ⁇ tetM (tetracycline resistance) cassette of pRN6680 (Nesin, et al. (1990) Antimicro. Agents. Chemother. 34:2273-2276) was blunt end ligated to the Nru ⁇ IEcol2 large fragment of plasmid pOI2 to form pOI4 ( Figure 5A).
- Plasmid pOI2 is pUC18 containing the 2.8 kB trxB Xbal DNA fragment, as described above.
- Plasmid pOI4 lacks a large internal segment of the trxB gene.
- Phage 011 transduction was performed to generate the desired gene replacement, as described by Novick, R.P. Meth. Enzymology 204:587-636.
- the phage was grown on one of the above integrants at 42°C in the presence of tetracycline and erythromycin and the lysate used to transduce S. aureus RN4220.
- TrxB_Sa The polypeptide sequence of TrxB from S. aureus shown in Figure 2 (and designated hereinafter of TrxB_Sa) was used to search for genes having similar sequences (and thus theoretically the same functional activity as S. aureus TrxB) in a variety of microorganisms.
- the database search tool BLAST Altschul, et al. (1990) J. Mol. Biol. 215:403-410) was employed to search the PathoSeqTM database, version 3.0 (Incyte Pharmaceuticals, Palo Alto, CA). Matches were found in the genomic sequence of Staphylococcus epidermidis 0-47 (available from Incyte) in the contiguous sequence (contig) designated SEP1c0392.
- TrxB_Sa and TrxB_Se were compared by aligning the full-length amino acid sequences using the GAP program. This program considers all possible alignments and gap positions and creates the alignment with the largest number of matched bases and the fewest gaps. A gap creation penalty and gap extension penalty is provided in units of matched bases. The program then creates a gap creation penalty number of matches for each gap it inserts. If a gap extension penalty greater than zero is used, the program also tracks, for each gap inserted, the length of the gap times the 36
- the GAP program uses the alignment method of Needleman and Wunsch (1970) J. Mol. Biol. 48:443-453.
- TrxB_Se and TrxB_Sa are shown in Figure 7.
- the sequences show about 90.4% identity and about 93.6% similarity (e.g., conservative amino acid substitutions).
- the gap weight was 12, length weight 4, quality 1470, ratio 4.727, average match 2.912, average mismatch -2.003, and gaps 0.
- the E. coli strain carrying pTRSE is grown and the
- TrxB_Se enzyme is isolated essentially as described in Example 3D and analyzed as in Example 1.
- Example 6 Inactivation of trxB Se A 750 bp segment internal to trxB_Se, corresponding to nt 11471-12221 , lacking N-terminal and C-terminal sequences coding for essential trxB nucleotide binding domains, is amplified by PCR employing the primers
- the amplified fragment is digested with the enzymes EcoRI and Hind ⁇ , and ligated into the vector pAUL-A which is digested with the 37
- the resulting plasmid is introduced into E. coli.
- the E. coli strain carrying pTRSE-int is grown and harvested and the plasmid pTRSE-int isolated.
- the plasmid is electroporated into S. epidermidis following the procedures described in Augustin, J. and Goetz, F. (1990) FEMS Microbiol. Lett. 68:203-208, employing selection for erythromycin resistance.
- a culture of S. epidermidis/pTRSE- ⁇ r ⁇ t is grown to mid-log phase in the presence of erythromycin then placed on TSA plates containing erythromycin.
- trxB_Se is an essential gene for growth.
- the plates are incubated at 42°C and the surviving colonies analyzed for integration of the pTRSE-int plasmid at the chromosomal trxB locus due to a single recombinational crossover event. Inability to isolate cells containing a disrupted trxB gene indicates that trxB_Se is an essential gene for growth.
- TrxB specifically reduces T-S 2 to T-(SH) 2 using NADPH [reaction (1)].
- the amount of reduced insulin is determined spectrophotometrically at 412 nm after denaturation with 6M guanidine-HCI in the presence of DTNB step 1 in 38
- Step I One hundred ⁇ l of a reaction mixture containing 0.3 mM insulin, 100 mM
- HEPES pH 7.5, 3 mM EDTA, 0.5 NADPH, and 1-20 ⁇ g of S. aureus TrxB is added to the wells of a series of 96 well microtiter plates. Thioredoxin is omitted from well 1.
- Wells 3 through 94 contain one of the following: a few ⁇ g of the test compound singly, either as a dry powder or in 1-5 ⁇ l of 50 mM Tris-HCI, pH 7.8, 50 mM NaCI buffer; a few ⁇ g each of a mixture of the test compounds either as a dry powder or in a few ⁇ l of 50 mM Tris-HCI, pH 7.8, 50 mM NaCI buffer, for uncharacterized mixtures of compounds derived from bacteria, fungi, plants, marine organisms and present in a few ⁇ l of water, buffer, or DMSO.
- the amount of compound employed is adjusted so that after all the additions are made the concentration of each compound is in the range of 1-10 ⁇ M.
- Wells 95 and 96 do not contain any compound.
- To well 1 and to wells 3-96 is added 10 ⁇ l of S. aureus TrxB solution containing approximately 300 pmoles in order to start the reaction. Water is added before the addition of TrxB to adjust the volume of each well to 150 ⁇ l. The plate is incubated at 37°C for 20 min. The reaction is terminated by the addition of 150 ⁇ l of 0.4 mg/ml DTNB/6 M guanidine hydrochloride in 0.2 M Tris-HCI, pH 8.0 and the absorbance at 412 nm is measured. All compounds that show inhibition of the DTNB reaction are further tested in step II.
- EDTA is added to all the wells of a series of 96 well microtiter plates.
- Thioredoxin solution 10 ⁇ l, is added to wells 3-96 to reach 3-8 ⁇ M concentration.
- Wells 3 through 94 also contain one of the following samples that exhibited inhibition of the
- DTNB reaction in step I a few ⁇ g of single compounds either as a dry powder or in 39
- the reaction is started by the addition of 10 ⁇ l dithiothreitol (DTT) to wells 2-95 to reach a final concentration of 0.3-0.5 mM.
- DTT dithiothreitol
- the plate is thoroughly agitated and placed in a plate reader and the absorbance at 650 nm is determined. The absorbance is read at intervals of 0.5 min for 80 min. In a typical reaction in the control well 2, containing only DTT and insulin, no precipitation is observed until after about 70 min. In the presence of T and DTT, precipitation appears after 10-15 min.
Abstract
Isolated and purified Staphylococcus thioredoxin reductases (TrxB) are provided. Polynucleotides encoding the TrxBs, vectors and host cells containing such polynucleotides are also provided. In addition, antibodies reactive with the TrxBs are provided, as are methods of isolating the TrxBs, as well as methods for producing recombinant TrxBs, using TrxBs for screening compounds for TrxB-modulating activity, and detecting Staphylococcus in a test sample.
Description
RECOMBINANT STAPHYLOCOCCUS THIOREDOXIN REDUCTASE, AND INHIBITORS THEREOF USEFUL AS ANTIMICROBIAL AGENTS
This application claims priority to the provisional application Serial No. 60/076,525 filed on March 2, 1998.
Technical Field
This invention relates generally to microbial metabolism and antimicrobial therapeutic agents. In particular, the invention relates to the bacterial enzyme thioredoxin reductase, to compounds that inhibit this enzyme, and to the use of these compounds as antimicrobial agents, particularly for the therapy of infections caused by Staphylococcus spp.
Background of the Invention
The thioredoxin system is composed of NADPH, thioredoxin (Trx) and the flavoenzyme thioredoxin reductase (TrxB). Trx reduction by TrxB involves two half- reactions. In the first half-reaction, the FAD prosthetic group of TrxB is reduced by NADPH and electrons are transferred to cysteines present in the active site of TrxB. In the second half-reaction, oxidized Trx is reduced by TrxB. The thioredoxin system serves to transfer reducing equivalents for reductive enzymes such as ribonucleotide reductase, methionine sulfoxide reductase and vitamin K epoxide reductase. It also mediates protein folding and exerts specific redox control of some transcription factors to modulate their binding to DNA.
The thioredoxin system is of particular importance for redox metabolism in some Gram-positive bacteria. In this regard, certain Gram-positive bacteria, such as staphylococci, lack detectable glutathione (GSH) and glutathione reductase (GSR) which together play a key role in maintaining intracellular thiol-disulfide balance. GSH is the predominant thiol produced by aerobic eukaryotes and some Gram-positive bacteria, is believed to protect aerobic organisms from oxygen toxicity, and participates in a multitude of functions. For example, GSH plays a pivotal role in management of oxidative stress and maintenance and regulation of
the redox balance. It acts as a cofactor for peroxide and ribonucleotide reductions, and serves in the conjugation and detoxification of foreign substances. Most organisms contain millimolar intracellular concentrations of GSH which, in concert with GSR and glutathione peroxidase, governs the redox status of the cellular environment. Thus, in microorganisms lacking the glutathione system, such as Staphylococcus aureus, the thioredoxin system, which is able to substitute for some of the glutathione-dependent processes, is of utmost importance.
The TrxB component of the thioredoxin system is a FAD-containing enzyme and belongs to a family of pyridine nucleotide-disulfide oxidoreductases. The bacterial enzyme obtained from Streptomyces clavuligerus, is a homodimer of 35 kDa subunits and has a native molecular weight of approximately 70 kDa. Aharonowitz et al. (1993) J. Bacteriol. 175:623-629. Each subunit of TrxB contains NADPH- and FAD- binding domains and includes an oxidoreductase active dithiol in the conserved sequence -CAT/VC-. Since the cysteine residues of TrxB are relatively inaccessible to the substrate thioredoxin, the enzyme appears to undergo a large conformational change during catalysis.
TrxBs from different mammalian species including calf (Holmgren, A. (1997) J. Biol. Chem. 252:4600-4606), rat (Luthman et al. (1982) Biochem. 2166628- 6633), and human (Arscott, et al. (1997) Proc. Natl. Acad. Sci. USA 94:3621-3626), have been purified and biochemically characterized. The rat liver TrxB has been isolated as a 116 kDa homodimer of 58 kDa subunits, and the mass of human placental TrxB estimated to be 160 kDa by gel-filtration chromatography and 130 kDa (two 65 kDa subunits) by sucrose density gradient centrifugation. The size difference between human TrxB and the smaller bacterial TrxBs is primarily due to differences in the dimer-interface domain. The redox-active cysteines of human TrxB are located in the FAD domain with a 4-amino acid bridge linking the two cysteines. The active-site disulfide of bacterial TrxBs, on the other hand, is located within the NADPH domain and a 2-amino acid bridge links the two cysteines. The 3D structure of the human TrxB is likely to be more similar to GSR than to the bacterial TrxB. Thus, primary amino acid sequence alignment of human TrxB with
bacterial TrxB sequences reveals just 23-31% identity, whereas alignment of the human TrxB with GSRs of different sources shows 35-44% identity. Arscott, et al. (1997) Proc. Natl. Acad. Sci. USA 94:3621-3626.
Based on the significant differences that exist between the bacterial and the mammalian trxB genes, and the enzymes encoded thereby, the bacterial TrxB provides a potential target for the development of novel antibacterial drugs with a high degree of selectivity.
Antimicrobial agents commonly used to combat bacterial infections generally interfere with one or more critical steps in the metabolism of the bacterium, resulting in growth inhibition or death of the microbe. However, pathogenic microorganisms, including staphylococci, are developing resistance, and in many cases multiple resistances, to existing antimicrobial agents. In this regard, S. aureus is an opportunistic pathogen of increasing medical concern. It can be aggressively invasive, spreading rapidly through soft tissues, directly invading bones and even entering the bloodstream to produce septic shock and disseminated intravascular coagulation. Infections caused by staphylococci generally fall within one of two categories: those related to toxins produced by the bacterium exclusively, including gastroenteritis, toxic shock syndrome, scalded skin syndrome, and the like; and those related to direct invasion and systemic spread of the organism, including dermal infections, bone and joint infections, staphylococcal pneumonia and empyema, meningitis, cerebritis, endocarditis, bacteremia, septic shock, and the like.
These staphylococcal infections have traditionally been treated with β-lactam antibiotics. However, strains of β-lactam antibiotic-resistant staphylococci (BLARS), such as methicillin-resistant S. aureus (MRSA), have developed and become a widespread cause of fatal nosocomial infection. Infections caused by such resistant staphylococci are treated predominantly with "last resort" antibiotics such as vancomycin. Since resistance to these antibiotics would essentially exhaust the current therapeutic arsenal, it is essential that new antibacterial agents be identified.
Summary of the Invention
The inventors herein have identified a bacterial thioredoxin reductase (TrxB) from Staphylococcus spp. that catalyzes, in two half-reactions, the specific NADPH- dependent reduction of thioredoxin (Trx), with the concomitant oxidation of NADPH to NADP+. In the first half-reaction, the FAD prosthetic group of TrxB is reduced by NADPH and electrons are transferred to cysteines present in the active site of TrxB. In the second half-reaction, oxidized Trx is reduced by TrxB.
The thioredoxin system provides a significant metabolic function in staphylococci and other Gram-positive bacteria that do not produce glutathione (GSH). The thioredoxin system catalyzes a broad range of protein thiol-disulfide exchange reactions, donates hydrogen for ribonucleotide reductase which is an essential enzyme in DNA synthesis, and is involved in redox regulation of numerous enzyme activities.
Staphylococcal TrxB differs significantly in its function from that of the mammalian enzyme in two important ways. First, it operates in an intracellular environment lacking GSH and GSH-dependent reductases. Second, its subunits are appreciably smaller than the mammalian enzyme and the dimeric enzyme possesses a substrate specificity distinct from its mammalian counterpart. Inhibition of Staphylococcal TrxB activity may cause depletion of reduced low molecular weight thiois, increase protein thiol oxidation, and interfere with DNA synthesis and radical scavenging. Such compromised cells are more likely to succumb to environmental challenges, such as those posed by the host immune system.
Consequently, bacterial TrxB provides an excellent target for the development of novel antibacterial drugs with a high degree of selectivity. Such antibacterials act by inhibiting TrxB, thereby incapacitating the target bacterium, with few or no side-effects to the eukaryotic host organism. As a result, inhibitors of TrxB activity are effective antimicrobial agents against Staphylococcus and other microorganisms that depend on TrxB for their redox reactions.
Accordingly, in one embodiment, the invention is directed to an isolated Staphylococcus TrxB polypeptide.
In another embodiment, the invention is directed to an isolated polynucleotide that encodes a Staphylococcus TrxB polypeptide.
In yet other embodiments, the invention is directed to a recombinant vector comprising the polynucleotide molecule, recombinant host cells transformed with the vector, and methods of producing recombinant polypeptides using the transformed cells.
In still a further embodiment, the invention is directed to an oligonucleotide probe capable of specifically hybridizing to a nucleic acid molecule encoding a Staphylococcus TrxB. The probe includes about 8 to about 50 contiguous nucleotides of the TrxB-encoding polynucleotide.
In still another embodiment of the invention, antibodies to a Staphylococcus TrxB polypeptide are provided.
In another embodiment, the invention is directed to a method of detecting the presence of Staphylococcus in a test sample suspected of containing a Staphylococcus, comprising:
(a) contacting the test sample with the oligonucleotide probe above, under conditions which allow a Staphylococcus polynucleotide, when present in the test sample, to hybridize with the oligonucleotide probe to form a hybrid complex; and
(b) detecting the presence or absence of the hybrid complex as an indication of the presence of a Staphylococcus in the test sample.
In yet another embodiment, the invention is directed to a method of detecting the presence of Staphylococcus in a test sample suspected of containing Stapylococcus, comprising:
(a) contacting the test sample with a TrxB antibody, under conditions which allow a Staphylococcus TrxB, when present in the test sample, to bind to the antibody to form an antibody-TrxB complex; and
(b) detecting the presence or absence of the antibody-TrxB complex, as an indication of the presence of Staphylococcus in the test sample.
In another embodiment, the invention is directed to a method of detecting a Staphylococcus in a test sample suspected of containing a Staphylococcus, comprising:
(a) incubating the test sample with a disulfide-containing substrate in the presence of thioredoxin and NADPH, under conditions that favor reduction of the disulfide-containing substrate, to produce a detectable signal when a Staphylococcus thioredoxin reductase is present;
(b) detecting the presence or absence of the signal; and
(c) correlating the presence of the signal with the presence of Staphylococcus in the test sample.
In yet further embodiments, the invention is directed to diagnostic kits comprising an oligonucleotide probe as above, a TrxB antibody, or a Staphylococcus TrxB polypeptide, and instructions for conducting the diagnostic test.
In another embodiment, the invention is directed to a method for identifying a compound that modulates Staphylococcus TrxB activity, comprising:
(a) providing a Staphylococcus TrxB polypeptide capable of catalyzing the specific reduction of thioredoxin with the concomitant oxidation of NADPH to NADP+;
(b) contacting a test compound with the TrxB polypeptide in the presence of thioredoxin, NADPH and a disulfide-containing substrate, under conditions that favor reduction of the disulfide-containing substrate;
(c) monitoring the presence of free sulfhydryl groups formed by the reduction of disulfides of the disulfide-containing substrate, as a measure of TrxB activity, thereby identifying a compound that modulates Staphylococcus TrxB activity. In yet further embodiments, the invention is directed to compounds identified by this method, compositions comprising the compounds and methods of treating Staphylococcus infections in an infected subject, comprising administering effective antibacterial amounts of the compositions.
In another embodiment, the invention is directed to a method for isolating a TrxB polypeptide from a Staphylococcus cell culture extract, comprising:
(a) performing a protein precipitation step with the cell culture extract to yield a first TrxB mixture;
(b) subjecting the first TrxB mixture to gel-filtration chromatography;
(c) identifying fractions from step (b) with TrxB activity; and
(d) performing anion-exchange chromatography on the fractions with TrxB activity to yield a product with a greater concentration of TrxB than the first TrxB mixture.
These and other embodiments of the present invention will readily occur to those of ordinary skill in the art in view of the disclosure herein.
Brief Description of the Figures
Figure 1 depicts the nucleotide sequence (SEQ ID NO:1) of the S. aureus trxB open reading frame.
Figure 2 shows the deduced amino acid sequence (SEQ ID NO:2) of S. aureus TrxB derived from the nucleotide sequence of the open reading frame.
Figure 3 is a diagram of vector pAUL-A.
Figure 4 is a diagram of disruption vector pOI7.
Figures 5A and 5B show the method used to construct the gene replacement vector pOI5. Figure 5A shows the construction of plasmid pOI4 used to construct plasmid pOI5, shown in Figure 5B.
Figure 6 depicts the nucleotide sequence (SEQ ID NO:9) of the S. epidermidis trxB open reading frame.
Figure 7 shows an alignment of the TrxB enzymes from S. aureus (designated TrxB_Sa, SEQ ID NO:2) and S. epidermidis (designated TrxB_Se, SEQ ID NO: 10). Colons indicate conservative amino acid substitutions and single dots indicate somewhat conservative substitutions.
Figure 8 is a flow chart depicting a method for identifying TrxB inhibitors using an insulin turbidity test.
Detailed Description
The practice of the present invention will employ, unless otherwise indicated, conventional techniques of molecular biology, microbiology and recombinant DNA technology, which are within the skill of the art. Such techniques are explained fully in the literature. See, e.g., Sambrook, Fritsch & Maniatis, Molecular Cloning: A Laboratory Manual, Second Edition (1989); DNA Cloning, Vols. I and II (D.N. Glover ed. 1985); the series, Methods In Enzymology (S. Colowick and N. Kaplan eds., Academic Press, Inc.); Scopes, Protein Purification: Principles and Practice (2nd ed., Springer-Verlag); and PCR: A Practical Approach (McPherson et al. eds. (1991) IRL Press).
All patents, patent applications and publications cited herein, whether supra or infra, are hereby incorporated by reference in their entirety.
As used in this specification and the appended claims, the singular forms "a," "an" and "the" include plural references unless the content clearly dictates otherwise.
Definitions
In describing the present invention, the following terms will be employed, and are intended to be defined as indicated below.
The term "polynucleotide" as used herein means a polymeric form of nucleotides of any length, either ribonucleotides or deoxyribonucleotides. This term refers only to the primary structure of the molecule. Thus, the term includes double- and single-stranded DNA, as well as double- and single-stranded RNA. It also includes modifications, such as by methylation and/or by capping, and unmodified forms of the polynucleotide. "Polypeptide" and "protein" are used interchangeably herein and indicate a molecular chain of amino acids linked through peptide bonds. The terms do not refer to a specific length of the product. Thus, peptides, oligopeptides, and proteins are included within the definition of polypeptide. The terms include post-translation modifications of the polypeptide, for example, glycosylations, acetylations,
phosphorylations, and the like. In addition, protein fragments, analogs, muteins, fusion proteins and the like are included within the meaning of polypeptide.
Thus, by "TrxB polypeptide" is meant a polypeptide, whether isolated, recombinant or synthetic, comprising an amino acid sequence identical to that depicted in Figures 2 (SEQ ID NO:2) or 10 (SEQ ID NO: 10), and fragments thereof that include as much of the molecule as necessary for the polypeptide to retain biological activity, e.g., catalytic and/or immunological activity, as well as analogs, mutated or variant proteins, and the like, thereof that retain such activity. Generally, if catalytic activity is required, the polypeptide will include the NADPH- and FAD- binding domains, as well as a redox active site. The NADPH domain is found at residues 146-161 of Figures 2 and 10. Two FAD domains are present, and found at residues 6-21 and 267-277, of Figures 2 and 10. Finally, the redox active site is found at residues 134-137 and includes the amino acid sequence CAVC. Thus, if catalytic activity is desired, the polypeptide can include about amino acid residues 1- 277 or more of Figures 2 or 10, or will include the above specified portions, with internal regions deleted, so long as catalytic activity is retained. If immunological activity is desired, e.g., the ability to raise antibodies for use in assays, immunopurification, and the like, the protein will contain one or more epitopes capable of eliciting a humoral antibody response. Normally, an epitope will include between about 3-20 amino acids, generally about 8-10, and preferably about 15-20 or more amino acids, derived from the TrxB molecule.
By sequence "similarity" between two amino acid sequences is meant an exact amino acid to amino acid comparison of two or more polypeptides at appropriate portions of the molecule, where identical amino acids are aligned, and where residues are not identical, aligned based on similar chemical and/or physical properties such as charge or hydrophobicity. "Percent similarity" can be determined between the compared polypeptide sequences using techniques well known in the art.
In general, "identity" refers to an exact nucleotide to nucleotide or amino acid to amino acid correspondence of two or more polynucleotide or polypeptide
10
sequences, respectively. Techniques for determining nucleic acid and amino acid "sequence identity" are well known in the art and include determining the nucleotide sequence of the mRNA for the gene of interest (usually via a cDNA intermediate) and determining the amino acid sequence encoded thereby, and comparing this to a second amino acid sequence. Programs available in the Wisconsin Sequence Analysis Package, Version 8 (available from Genetics Computer Group, Madison, Wl) for example, the GAP program, are capable of calculating both the identity between two polynucleotides and the identity and similarity between two polypeptide sequences. Other programs for calculating identity or similarity between sequences are known in the art.
Generally, a polypeptide analog of TrxB will have at least about 50% identity, preferably about 60% identity, more preferably about 75-85% identity, and most preferably about 90-95% or more identity, to the reference TrxB sequence. Further, the polypeptide may have at least about 60% similarity, preferably at least about 75% similarity, more preferably about 85% similarity, and most preferably about 95% or more similarity to the reference sequence. Additionally, a polynucleotide variant will display at least about 50% identity, preferably about 60% identity, more preferably about 75-85% identity, and most preferably about 90-95% or more identity, to the reference trxB nucleotide sequence. By the term "degenerate variant" or "structurally conserved mutation" is intended a polynucleotide containing changes in the nucleic acid sequence thereof, such as insertions, deletions or substitutions, that encodes a polypeptide having the same amino acid sequence as the polypeptide encoded by the polynucleotide from which the degenerate variant is derived. "Recombinant host cells," "host cells," "cells," "cell lines," "cell cultures," and other such terms denoting microorganisms or higher eukaryotic cell lines cultured as unicellular entities refer to cells which can be, or have been, used as recipients for recombinant vectors or other transfer DNA, immaterial of the method by which the DNA is introduced into the cell or the subsequent disposition of the cell. The terms include the progeny of the original cell which has been transfected.
11
A "vector" is a replicon in which another polynucleotide segment is attached, such as to bring about the replication and/or expression of the attached segment. The term includes expression vectors, cloning vectors, and the like.
The term "control sequence" refers to a polynucleotide sequence which effects the expression of coding sequences to which it is ligated. The nature of such a control sequence differs depending upon the host organism. In prokaryotes, such control sequences generally include a promoter, a ribosomal binding site, and a terminator. In eukaryotes, such control sequences generally include a promoter, a terminator and, in some instances, an enhancer. The term "control sequence" thus is intended to include at a minimum all components necessary for expression, and also may include additional components whose presence is advantageous, for example, leader sequences.
A "coding sequence" is a polynucleotide sequence that is transcribed into mRNA and/or translated into a polypeptide when placed under the control of appropriate regulatory sequences. The boundaries of the coding sequence are determined by a translation start codon at the 5'-terminus and a translation stop codon at the 3'-terminus. A coding sequence can include, but is not limited to, mRNA, cDNA, and recombinant polynucleotide sequences. Mutants or analogs may be prepared by the deletion of a portion of the coding sequence, by insertion of a sequence, and/or by substitution of one or more nucleotides within the sequence. Techniques for modifying nucleotide sequences, such as site-directed mutagenesis, are well known to those skilled in the art. See, e.g., Sambrook et al., supra; DNA Cloning, Vols. I and II, supra; Nucleic Acid Hybridization, supra.
"Operably linked" refers to a situation wherein the components described are in a relationship permitting them to function in their intended manner. Thus, for example, a control sequence "operably linked" to a coding sequence is ligated in such a manner that expression of the coding sequence is achieved under conditions compatible with the control sequences. A coding sequence may be operably linked to control sequences that direct the transcription of the polynucleotide whereby said polynucleotide is expressed in a host cell.
12
"Transformation" refers to the insertion of an exogenous polynucleotide into a host cell, irrespective of the method used for the insertion, or the molecular form of the polynucleotide that is inserted. For example, injection, direct uptake, transduction, and f-mating are included. Furthermore, the insertion of a polynucleotide per se and the insertion of a plasmid or vector comprised of the exogenous polynucleotide, are also included. The exogenous polynucleotide may be directly transcribed and translated by the cell, maintained as a nonintegrated vector, for example, a plasmid, or alternatively, may be stably integrated into the host genome. The term "probe" denotes a defined nucleic acid segment which can be used to identify a specific polynucleotide present in samples bearing the complementary sequence. A probe will generally include about 8 to about 75 contiguous nucleic acids of the reference polynucleotide, generally about 12 to about 50 contiguous nucleic acids, and preferably about 15-18 to about 30 contiguous nucleic acids of the reference sequence.
The term "isolated," when referring to a polynucleotide or a polypeptide, intends that the indicated molecule is present in the substantial absence of other similar biological macromolecules of the same type. The term "isolated" as used herein means that at least 75 wt.%, more preferably at least 85 wt.%, more preferably still at least 95 wt.%, and most preferably at least 98 wt.% of a composition is the isolated polynucleotide or polypeptide. An "isolated polynucleotide" that encodes a particular polypeptide refers to a polynucleotide that is substantially free of other nucleic acid molecules that do not encode the subject polypeptide; however, the molecule may include conservative mutations as defined herein. Thus, an isolated polynucleotide would not be a polynucleotide as it exists on the chromosome.
The term "test sample" refers to a component of an individual's body which is the source of an analyte, such as antibodies or antigens of interest. These test samples include biological samples which can be tested by the methods of the present invention described herein and include human and animal body fluids such
13
as whole blood, serum, plasma, cerebrospinal fluid, urine, lymph fluids, and various external secretions of the respiratory, intestinal and genitorurinary tracts, tears, saliva, milk, white blood cells, myelomas and the like; biological fluids such as cell culture supematants; fixed tissue specimens; and fixed cell specimens.
The following single-letter amino acid abbreviations are used throughout the text:
Alanine A Arginine R
Asparagine N Aspartic acid D
Cysteine C Glutamine Q
Glutamic acid E Glycine G
Histidine H Isoleucine I
Leucine L Lysine K
Methionine M Phenylalanine F
Proline P Serine S
B. General Methods
The present invention is based on the identification of novel Staphylococcal TrxB polypeptides, including S. aureus TrxB (also termed TrxB_Sa herein) and S. epidermidis TrxB (also termed TrxB_Se herein), as well as polynucleotides encoding the TrxBs, and methods of making the TrxBs. The invention includes not only the enzyme but also methods for screening compounds for pharmacological activity using the enzyme, cells expressing the enzyme, antibodies to the enzyme and the use of polynucleotides and antibodies to diagnose the presence of Staphylococcus in a test sample.
In particular, the inventors herein have identified new TrxB enzymes in S. aureus and S. epidermidis. The native enzyme has a molecular mass (Mr) of approximately 70 kDa, as determined by gel filtration chromatography. The enzyme exists as a homodimer having a subunit Mr of about 35 kDa, as determined by SDS
14
polyacrylamide gel electrophoresis. The predicted value of the Staphylococcal TrxB subunit molecular mass, based on the primary amino acid sequence is 33.518, and the calculated isoelectric point (PI) is 5.39. The gene encoding the S. aureus TrxB enzyme has been cloned and the ORF coding for the TrxB protein is shown in Figure 1. The gene encodes a putative amino acid sequence of 311 amino acids, shown in Figure 2.
Similarly, the gene encoding the S. epidermidis TrxB enzyme has been identified and the nucleotide and amino acid sequences are shown in Figures 6 and 7, respectively. The enzyme can be isolated directly from bacteria as follows. Bacteria are cultured in a suitable culture medium, such as trypticase soy broth (TSB). The bacteria are then removed from the culture medium using standard techniques known in the art, such as by centrifugation or microfiltration or a combination of the two. For example, microfiltration using an appropriate filter will suffice to remove unwanted cellular debris.
Bacteria thus obtained are prepared to release the contents of the cytoplasm. Bacterial cells may be broken using methods and/or reagents known in the art that do not adversely affect the structure and/or the activity of the TrxB, e.g., exposure to freeze-thaw cycles, exposure to an ultrasonic disintegrator, homogenization, bead milling, chemical or enzymatic cell lysis, and the like. In one preferred method, cells are incubated in a buffer containing lysostaphin, a lytic agent for S. aureus, and then centrifuged to remove insoluble cellular debris.
The bacterial cell extract thus prepared can be further processed to separate the protein from the cellular debris, and provide an initial stage of purification and volume reduction. For example, the extract obtained from the previous step may be processed by a primary separation procedure such as ultrafiltration, i.e., passage through a filter having an appropriate molecular weight cut-off, to concentrate the sample by reducing the water and salt content. Alternatively, the extract may be precipitated by neutral salts such as ammonium sulphate, organic solvents such as ethanol, or other agents for recovering and purifying the protein. Preferably,
15
Staphylococcus TrxB is precipitated from the extract by adding ammonium sulfate to the extract to approximately 30% to 50% saturation, preferably 40% saturation. The supernatant of the same is collected by, e.g., centrifugation, and the ammonium sulfate is adjusted to about 70% to 90%, preferably 80% saturation. The treated precipitate thus obtained is collected and used in further purification steps.
A number of protein purification operations may be used to further purify the Staphylococcus TrxB including adsorption chromatography, ion-exchange chromatography, hydrophobic interaction chromatography, affinity chromatography, chromatofocussing, gel-filtration, reversed-phase liquid chromatography, phosphocellulose chromatography, hydroxyapatite chromatography or lectin chromatography, any combination of such techniques. Protein refolding steps can be used, as necessary, in completing configuration of the protein. Finally, high performance liquid chromatography (HPLC) can be employed for final purification steps. For example, the fraction precipitating between 40-80% ammonium sulfate saturation can be applied to a gel-filtration matrix for size separation. Useful matrices for size separation include any of several known in the art such as, without limitation, those made of dextran, dextran/bisacrylamide, polyacrylamide, agarose, cross-linked agarose, agarose/polyacrylamide, and cross-linked polyethers. Particularly preferred matrices are those which allow fractionation of molecules in the size range of about 104 to 106, such as Sephacryl S-300, Sepharose 6B, Sepharose CL-6B, Ultragel AcA44, Ultragel AcA34, Ultragel A6, and the like.
Fractions from the size-separation step which exhibit TrxB and Trx activity can be pooled and applied to an ion-exchange column and proteins eluted with a linear salt gradient. Preferred ion-exchangers are anion-exchangers, well known in the art. Particularly preferred herein are relatively weak anion-exchangers, such as those including aminoethyl (AE) or diethylaminoethyl (DEAE) functionalities. Useful matrix materials include but are not limited to, cellulose matrices, such as fibrous, microgranular and beaded matrices; agarose, dextran, polyacrylate, polyvinyl,
16
polystyrene, silica and polyether matrices; and composites. A representative anion- exchanger for use herein is DEAE-Sepharose.
TrxB activity can be monitored during purification using standard TrxB assays. For example, the presence of TrxB can be assayed spectrophotometrically by monitoring the NADPH- and TrxB disulfide-dependent reduction of a disulfide- containing substrate. One assay method monitors the reduction of 5,5'-dithio-6/s-2- nitrobenzoic acid (DTNB) at 412 nm. See, e.g., Ellman (1959) Arch. Biochem. Biophys. 82:70-77. A particularly preferred assay uses insulin as the disulfide- containing substrate. The presence of free sulfhydryl (SH) groups in insulin are measured at 650 nm as an indication of TrxB activity. See, e.g., A. Holmgren and M. Bjornstedt, (1995) Methods in Enzymology 252:199-208; and the examples herein. In this reaction, TrxB specifically reduces thioredoxin (T-S2) to T-(SH)2 using NADPH. The formed T-(SH)2 in turn reduces native insulin. Insulin can be replaced by any of several low molecular weight disulfide compounds in the assay, such as cystine, and TrxB activity is monitored spectrophotometrically following the oxidation of NADPH.
Following isolation, purity of fractions showing TrxB activity can be determined using any of several methods such as by SDS-PAGE.
Once purified, the amino acid sequences of the proteins can be determined, e.g., by repetitive cycles of Edman degradation, followed by amino acid analysis by HPLC. Other methods of amino acid sequencing are also known in the art. Based on knowledge of the amino acid sequence, DNA encoding the enzyme can be derived from genomic or cDNA, prepared by synthesis, or by a combination of techniques. The DNA can then be used to express the TrxB, or as a template for the preparation of RNA, using methods well known in the art (see, Sambrook et al., supra).
More particularly, DNA encoding the Staphylococcus TrxB may be obtained from an appropriate DNA library, e.g., an S. aureus or S. epidermidis genomic DNA library. DNA libraries may be probed using the procedure described by Grunstein et al. (1975) Proc. Natl. Acad. Sci. USA 73:3961. Briefly, the DNA to be probed is
17
immobilized on nitrocellulose filters, denatured and prehybridized with a buffer which contains 0-50% formamide, 0.75 M NaCI, 75 mM Na citrate, 0.02% (w/v) each of bovine serum albumin (BSA), polyvinyl pyrollidone and Ficoll®, 50 mM Na phosphate (pH 6.5), 0.1% sodium dodecyl sulfate (SDS) and 100 μg/ml carrier denatured DNA. The percentage of formamide in the buffer, as well as the time and temperature conditions of the prehybridization and subsequent hybridization steps, depends on the stringency required. Oligomeric probes which require lower stringency conditions are generally used with low percentages of formamide, lower temperatures, and longer hybridization times. Probes containing more than 30 or 40 nucleotides such as those derived from cDNA or genomic sequences generally employ higher temperatures, for example, about 40°C to 42°C, and a high percentage, for example, 50%, formamide. Following prehybridization, a 32P-labelled oligonucleotide probe is added to the buffer, and the filters are incubated in this mixture under hybridization conditions. After washing, the treated filters are subjected to autoradiography to show the location of the hybridized probe. DNA in corresponding locations on the original agar plates is used as the source of the desired DNA.
Synthetic oligonucleotides may be prepared using an automated oligonucleotide synthesizer such as that described by Warner (1984) DNA 3:401. If desired, the synthetic strands may be labeled with 32P by treatment with polynucleotide kinase in the presence of 32P-ATP, using standard conditions for the reaction. DNA sequences including those isolated from genomic or cDNA libraries, may be modified by known methods which include site-directed mutagenesis as described by Zoller (1982) Nucleic Acids Res. 10:6487. Briefly, the DNA to be modified is packaged into phage as a single stranded sequence, and converted to a double stranded DNA with DNA polymerase using, as a primer, a synthetic oligonucleotide complementary to the portion of the DNA to be modified, and having the desired modification included in its own sequence. Cultures of the transformed bacteria, which contain replications of each strand of the phage, are plated in agar to obtain plaques. Theoretically, 50% of the new plaques contain phage having the
18
mutated sequence, and the remaining 50% have the original sequence. Replicates of the plaques are hybridized to labeled synthetic probe at temperatures and conditions suitable for hybridization with the correct strand, but not with the unmodified sequence. The sequences which have been identified by hybridization are recovered and cloned.
Once produced, the DNA may then be incorporated into a cloning or expression vector for replication in a suitable host cell. Vector construction employs methods known in the art. Generally, site-specific DNA cleavage is performed by treating with suitable restriction enzymes under conditions which generally are specified by the manufacturer of these commercially available enzymes. Usually, about 1 microgram (μg) of plasmid or DNA sequence is cleaved by 1-10 units of enzyme in about 20 μl of buffer solution by incubation at 37°C for 1 to 2 hours. After incubation with the restriction enzyme, protein is removed by phenol/chloroform extraction and the DNA recovered by precipitation with ethanol. The cleaved fragments may be separated using polyacrylamide or agarose gel electrophoresis methods, according to methods known by those of skill in the art.
Sticky end cleavage fragments may be blunt ended using E. coli DNA polymerase 1 (Klenow) in the presence of the appropriate deoxynucleotide triphosphates (dNTPs) present in the mixture. Treatment with S1 nuclease also may be used, resulting in the hydrolysis of any single stranded DNA portions.
Ligations are performed using standard buffer and temperature conditions using T4 DNA ligase and ATP. Sticky-end ligations require less ATP and less ligase than blunt-end ligations. When vector fragments are used as part of a ligation mixture, the vector fragment often is treated with bacterial alkaline phosphatase (BAP) or calf intestinal alkaline phosphatase to remove the 5'-phosphate and thus prevent religation of the vector. Alternatively, restriction enzyme digestion of unwanted fragments can be used to prevent ligation.
For standard vector constructions, ligation mixtures are transformed into a suitable host, and successful transformants selected by antibiotic resistance or other markers. Plasmids from the transformants can then be prepared according to the
19
method of Clewell et al. (1969) Proc. Natl. Acad. Sci. USA 62:1159 usually following chloramphenicol amplification as reported by Clewell et al. (1972) J. Bacteriol. 110:667. The DNA is isolated and analyzed usually by restriction enzyme analysis and/or sequencing. Sequencing may be by the well-known dideoxy method of Sanger et al. (1977) Proc. Natl. Acad. Sci. USA 74:5463) as further described by Messing et al. (1981) Nucleic Acid Res. 9:309, or by the method reported by Maxam et al. (1980) Meth. Enzymol. 65:499. Problems with band compression, which are sometimes observed in GC rich regions, are overcome by use of T-deazoguanosine according to the method reported by Barr et al. (1986) Biotechniques 4:428. Host cells are genetically engineered (transduced, transformed, or transfected) with the vectors of this invention which may be a cloning vector or an expression vector. The vector may be in the form of a plasmid, a viral particle, a phage, etc. The engineered host cells can be cultured in conventional nutrient media modified as appropriate for activating promoters, selecting transformants or amplifying the TrxB-encoding polynucleotide. The culture conditions, such as temperature, pH and the like, are those previously used with the host cell selected for expression, and will be apparent to those of skill in the art.
Both prokaryotic and eukaryotic host cells may be used for expression of desired coding sequences when appropriate control sequences that are compatible with the designated host are used. Among prokaryotic hosts, E. coli is frequently used. Expression control sequences for prokaryotes include promoters, optionally containing operator portions, and ribosome binding sites. Transfer vectors compatible with prokaryotic hosts are commonly derived from the plasmid pBR322 that contains operons conferring ampicillin and tetracycline resistance, and the various pUC vectors, that also contain sequences conferring antibiotic resistance markers. These markers may be used to obtain successful transformants by selection. Commonly used prokaryotic control sequences include the β-lactamase (penicillinase), lactose promoter system (Chang et al. (1977) Nature 198:1056), the tryptophan promoter system (reported by Goeddel et al. (1980) Nucleic Acid Res. 8:4057) and the lambda-derived PI promoter and N gene ribosome binding site
20
(Shimatake et al. (1981) Nature 292:128) and the hybrid Tac promoter (De Boer et al. (1983) Proc. Natl. Acad. Sci. USA 292:128) derived from sequences of the trp and lac UV5 promoters. The foregoing systems are particularly compatible with E. coli; however, other prokaryotic hosts such as strains of Bacillus or Pseudomonas may be used if desired, with corresponding control sequences.
Eukaryotic hosts include yeast and mammalian cells in culture systems. Saccharomyces cerevisiae and S. carlsbergensis are commonly used yeast hosts, and are convenient fungal hosts. Yeast-compatible vectors carry markers that permit selection of successful transformants by conferring protrophy to auxotrophic mutants or resistance to heavy metals on wild-type strains. Yeast compatible vectors may employ the 2-micron origin of replication (Broach et al. (1983) Meth. Enzymol. 101 :307), the combination of CEN3 and ARS1 or other means for assuring replication, such as sequences that will result in incorporation of an appropriate fragment into the host cell genome. Control sequences for yeast vectors are known in the art and include promoters for the synthesis of glycolytic enzymes, including the promoter for 3-phosphoglycerate kinase. See, for example, Hess et al. (1968) J. Adv. Enzyme Reg. 7:149, Holland et al. (1978) Biochemistry 17:4900, and Hitzeman (1980) J. Biol. Chem. 255:2073. Terminators also may be included, such as those derived from the enolase gene as reported by Holland (1981) J. Biol. Chem. 256:1385. It is contemplated that particularly useful control systems are those that comprise the glyceraldehyde-3-phosphate dehydrogenase (GAPDH) promoter or alcohol dehydrogenase (ADH) regulatable promoter, terminators also derived from GAPDH, and, if secretion is desired, leader sequences from yeast alpha factor. In addition, the transcriptional regulatory region and the transcriptional initiation region which are operably linked may be such that they are not naturally associated in the wild-type organism.
Mammalian cell lines available as hosts for expression are known in the art and include many immortalized cell lines which are available from the American Type Culture Collection. These include HeLa cells, Chinese hamster ovary (CHO) cells, baby hamster kidney (BHK) cells, and others. Suitable promoters for
21
mammalian cells also are known in the art and include viral promoters such as that from Simian Virus 40 (SV40), Rous sarcoma virus (RSV), adenovirus (ADV), bovine papilloma virus (BPV), cytomegalovirus (CMV). Mammalian cells also may require terminator sequences and poly A addition sequences; enhancer sequences which increase expression also may be included, and sequences which cause amplification of the gene also may be desirable. These sequences are known in the art. Vectors suitable for replication in mammalian cells may include viral replicons, or sequences which insure integration of the appropriate sequences encoding the Staphylococcus TrxB into the host genome. Other eukaryotic systems are also known, as are methods for introducing polynucleotides into such systems, such as into amphibian cells, using known methods, and insect cells using methods described in Summers and Smith (1987), Texas Agricultural Experiment Station Bulletin No. 1555, and the like.
Transformation may be by any known method for introducing polynucleotides into a host cell, including packaging the polynucleotide in a virus and transducing a host cell with the virus, by direct uptake of the polynucleotide by the host cell, and the like. The transformation procedures selected depend upon the host to be transformed. Bacterial transformation by direct uptake generally employs treatment with calcium or rubidium chloride. Cohen (1972) Proc. Natl. Acad. Sci. USA 69:2110. Yeast transformation by direct uptake may be conducted using the calcium phosphate precipitation method of Graham et al. (1978) Virology 52:526, or modification thereof.
Expression of active TrxB can be assayed spectrophotometrically, as described above, by monitoring the NADPH- and TrxB disulfide-dependent reduction of a disulfide-containing substrate. Particularly useful substrates include DTNB and insulin. See, e.g., Ellman (1959) Arch. Biochem. Biophys. 82:70-77; and A. Holmgren and M. Bjomstedt, (1995) Methods in Enzymology 252:199-208. Alternatively, expression of TrxB can be monitored using an ELISA assay and antibodies prepared to the isolated TrxB enzyme. The enzyme is recovered and
22
purified from recombinant host cell cultures expressing the same by known methods as described above.
The Staphylococcus TrxB polypeptide or fragments thereof, may also be synthesized by conventional techniques known in the art, for example, by chemical synthesis such as solid-phase peptide synthesis. In general, these methods employ either solid- or solution- phase synthesis methods, well known in the art. See, e.g., J. M. Stewart and J. D. Young, Solid Phase Peptide Synthesis, 2nd Ed., Pierce Chemical Co., Rockford, IL (1984) and G. Barany and R. B. Merrifield, The Peptides: Analysis, Synthesis, Biology, editors E. Gross and J. Meienhofer, Vol. 2, Academic Press, New York, (1980), pp. 3-254, for solid phase peptide synthesis techniques; and M. Bodansky, Principles of Peptide Synthesis, Springer-Verlag, Berlin (1984) and E. Gross and J. Meienhofer, Eds., The Peptides: Analysis, Synthesis, Biology, supra, Vol. 1 , for classical solution synthesis.
Once obtained, the enzyme may be used to identify compounds that modulate Staphylococcus TrxB activity. Thus, as described above, enzyme activity and the effects of compounds on enzyme activity can be assayed spectrophotometrically by monitoring the NADPH- and TrxB disulfide-dependent reduction of 5,5'-dithio-ιb/s-2-nitrobenzoic acid (DTNB) at 412 nm, or by measuring the presence of free SH groups of insulin at 650 nm. Purification or expression of Staphylococcus TrxB, and screening for compounds that inhibit the enzyme activity, provides a method for rapid selection of compounds with enzyme-inhibiting activity.
Compounds that inhibit Staphylococcus TrxB are considered potential therapeutic agents for use in treating several disorders caused by staphylococcal bacteria, including without limitation those caused by S. aureus, S. epidermidis, S. albus, S. hyicus, S. hyos, S. intermedius, S. simulans, and the like. These bacteria cause infection in man and other nonhuman primates, as well as in domestic animals, such as dogs and cats, and in farm animals, including horses, pigs, sheep, goats and cows. These agents are therefore useful in preventing or retarding
23
growth and/or reproduction of the infecting microorganism in a wide variety of vertebrate subjects.
Examples of diseases for which TrxB inhibitors are useful therapeutic agents include any of the several infections caused by staphylococci including, but not limited to, gastroenteritis, enterocolitis, toxic shock syndrome, scalded skin syndrome, dermal infections, cellulitis, toxic epidermal necrolysis, ecthyma, necrotizing fasciitis, folliculitis, furuncles, carbuncles, impetigo, bone and joint infections, osteomyelitis, pneumonia and empyema, meningitis, cerebritis, endocarditis, bacteremia, septic shock, septicemia, food poisoning, enteritis, and the like.
The inhibitory compounds of the present invention can be formulated into pharmaceutical compositions in a variety of dosage forms such as, but not limited to, liquid solutions or suspensions, tablets, pills, powders, ointments suppositories, polymeric microcapsules or microvesicles, liposomes, and injectable or infusible solutions. The preferred form depends upon the mode of administration and the particular microorganism and disease targeted. The compositions also preferably include pharmaceutically acceptable vehicles, carriers or adjuvants, well known in the art, such as human serum albumin, ion exchangers, alumina, lecithin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, and salts or electrolytes such as protamine sulfate. Suitable vehicles are, for example, water, saline, dextrose, glycerol, ethanol, or the like, and combinations thereof. Actual methods of preparing such compositions are known, or will be apparent, to those skilled in the art. See, e.g., Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, Pennsylvania, 18th edition, 1990. The above compositions can be administered using conventional modes of delivery including, but not limited to, intramuscular, intravenous, intraperitoneal, oral, intralymphatic, or subcutaneous administration. Local administration to a tissue in question, or to a site of infection, e.g., direct injection into an infected joint, will also find use with the present invention.
24
Therapeutically effective doses will be easily determined by one of skill in the art and will depend on the severity and course of the disease, the patient's health and response to treatment, and the judgment of the treating physician.
Furthermore, the Staphylococcus TrxB polypeptide can be used to prepare polyclonal or monoclonal antibodies using techniques that are well known in the art. If polyclonal antibodies are desired, a selected mammal, (e.g., mouse, rabbit, goat, horse, etc.) is immunized with a TrxB polypeptide and serum from the immunized animal is collected and treated according to known procedures. See, e.g., Jurgens et al. (1985) J. Chrom. 348:363-370. If serum containing polyclonal antibodies is used, the polyclonal antibodies can be purified by immunoaffinity chromatography, using known procedures.
Monoclonal antibodies to the TrxB polypeptides can also be readily produced by one skilled in the art. The general methodology for making monoclonal antibodies using hybridoma technology is well known. Immortal antibody-producing cell lines can be created by cell fusion, as well as by other techniques, such as direct transformation of B-lymphocytes with oncogenic DNA, or transfection with Epstein-Barr virus. See, e.g., M. Schreier er al., Hybridoma Techniques (1980); Hammerling et al., Monoclonal Antibodies and T-cell Hybridomas (1981); Kennett et al., Monoclonal Antibodies (1980); U.S. Patent Nos. 4,341 ,761 ; 4,399,121 ; 4,427,783; 4,444,887; 4,452,570; 4,466,917; 4,472,500, 4,491 ,632; and 4,493,890. Panels of monoclonal antibodies produced against the TrxB polypeptides can be screened for various properties; e.g., for isotype, epitope, affinity, etc. Monoclonal antibodies are useful in purification, using immunoaffinity techniques, of the TrxB polypeptides. Monoclonal and polyclonal antibodies that display specificity and selectivity for the enzyme can be labeled with a detectable moiety, e.g., a fluorescent moiety, and used in in vitro, or in situ immunofluorescent assays, or the like. The antibodies can be used to identify Staphylococcus for immunodiagnostic purposes.
In addition, DNA encoding the Staphylococcus TrxBs, or RNA derived therefrom, can be used to design oligonucleotide probes for Staphylococcus present
25
in a host organism. As used herein, the term "probe" refers to a structure comprised of a polynucleotide, as defined above, which contains a nucleic acid sequence complementary to a nucleic acid sequence present in a target polynucleotide. The polynucleotide regions of probes may be composed of DNA, and/or RNA, and/or synthetic nucleotide analogs such as morpholino compounds and peptide nucleic acid ("PNA") analogs. Such probes may be used in in vitro or in situ hybridization assays, or the like, and are useful, for example, for the diagnosis of microbial infections.
Using a determined portion of the isolated TrxB-encoding polynucleotide, oligomers of approximately eight or more nucleotides can be prepared, either by excision or synthetically, which hybridize with the TrxB-encoding polynucleotide. Such oligomers are useful, for example, for detecting the presence of bacteria in diseased individuals. The natural or derived probes for trxB polynucleotides are a length that allows the detection of unique sequences by hybridization. While 6-8 nucleotides may be a workable length, sequences of 10-12 nucleotides are preferred, and those of about 18-20 nucleotides, or more, most preferred. These probes can be prepared using routine, standard methods including automated oligonucleotide synthetic methods.
When the oligonucleotide probes are to be used as diagnostic reagents, the test sample to be analyzed, such as blood or serum, may be treated such as to extract a nucleic acid fraction thereof. The resulting nucleic acid from the sample may be subjected to gel electrophoresis or other size separation techniques, or the nucleic acid sample may be dot-blotted without size separation. The sample is then exposed to an oligonucleotide probe that has been detectably labeled. Suitable labels and methods for attaching labels to probes are known in the art, and include but are not limited to radioactive labels incorporated by nick translation or kinasing, biotin, fluorescent and chemiluminescent probes, enzymes which catalyze the production of a detectable product such as horseradish peroxidase, alkaline phosphatase, β-galactosidase, and the like. The nucleic acids extracted from the
26
sample are then treated with the labeled probe under conditions of suitable hybridization stringency.
The stringency of hybridization is determined by a number of factors during the washing procedure, including temperature, ionic strength, length of time and concentration of formamide. Sambrook et al., supra. Hybridization can be carried out by a number of techniques. Amplification of the sample nucleic acid, if required, can be performed, for example, by ligase chain reaction (LCR), polymerase chain reaction (PCR), Q-beta replicase, NASBA, or other techniques well known in the art. The amplified nucleic acids then may be detected using a hybridization assay such as those known in the art.
TrxB, antibodies thereto, as well as polynucleotides encoding TrxB or portions thereof, can be provided in diagnostic kits. For example, oligomer probes capable of specifically hybridizing to a polynucleotide encoding a TrxB can be packaged in diagnostic kits which include the probe nucleic acid sequence which may be labelled. Alternatively, the probe may be provided unlabelled and the ingredients for labelling can be included with the kit. The kit also may contain other suitably packaged reagents and materials needed or desirable for the particular hybridization protocol, for example, standards as well as instructions for performing the assay.
In addition, kits can include reagents for detecting of the presence and/or amount of Staphylococcus TrxB in a test sample, as well as for detecting the presence of Staphylococcus. Such reagents can comprise, e.g., an antibody capable of specifically binding to the TrxB polypeptide.
Furthermore, kits containing a Staphylococcus TrxB polypeptide in a suitable container are provided for screening compounds for TrxB-modulating activity or for screening test samples for the presence of a TrxB antibody. It is contemplated that reagents employed in the above kits can be provided in one or more containers such as vials or bottles, with each container containing a separate reagent such as a monoclonal antibody, or a cocktail of monoclonal antibodies, or a polypeptide (either recombinant or synthetic) employed in the assay. Other components such as
27
buffers, controls, and the like, known to those of ordinary skill in art, may be included in such test kits. The kits will also include instructions for the use thereof.
Below are examples of specific embodiments for carrying out the present invention. The examples are offered for illustrative purposes only, and are not intended to limit the scope of the present invention in any way.
Efforts have been made to ensure accuracy with respect to numbers used (e.g., amounts, temperatures, etc.), but some experimental error and deviation should, of course, be allowed for.
C. Experimental
Example 1 Identification of a Thioredoxin Reductase from S. aureus In order to identify the enzyme responsible for the reduction of oxidized thioredoxin (Trx), S. aureus extracts were analyzed for thioredoxin reductase (TrxB) activity on oxidized thioredoxin in a NADPH-dependent reaction specific for the reduction of insulin as the protein disulfide substrate. 10 ml of an overnight culture of S. aureus RN8325-4 (obtained from Richard Novick at New York University School of Medicine), grown at 37°C in tryptic soy broth (TSB) medium (Difco Laboratories, Detroit, Ml), was used to inoculate 0.5 L fresh sterilized TSB medium and the culture was grown for 4 hours. Cells were harvested by centrifugation (8000 x g, 15 min), resuspended in 50 mM Tris HCI buffer (20 ml) containing 1 mM EDTA and disrupted by sonication. The homogenized suspension was cleared from insoluble cellular debris by centrifugation and saved. The supernatant was brought to a final concentration of 1% streptomycin sulfate, stirred for 30 min and the nucleic acid precipitate removed by centrifugation. Ammonium sulfate was added to the clear liquid and the fraction that precipitated between 40-80% ammonium sulfate saturation was collected by centrifugation, dissolved in a minimal volume of buffer and chromatographed on a AcA44 gel-filtration size column.
Fractions exhibiting TrxB activity were separated from those containing the Trx activity and served as the high and low molecular weight protein components.
28
respectively, in the thioredoxin assay. High molecular weight protein fractions were added to a reaction mixture containing an excess of Trx, NADPH and insulin, and the formation of free sulfhydryl (SH) groups in insulin was detected by titration with 5,5'-dithio-jb s-2-nitrobenzoic acid (DTNB), which forms a yellow product (TNB, absorbance maximum at 412 nm) on interaction with free thiois. The reduction of the insulin disulfides is strictly dependent on the presence of each of reaction components (NADPH, TrxB, Trx). DTNB may be used in place of insulin as the substrate for the Trx-driven reaction, but is less specific. See, e.g., Ellman (1959) Arch. Biochem. Biophys. 82:70-77.
A typical assay (Table 1) consisted of a 40 μl fraction of the high molecular weight component from the AcA44 gel-filtration column to which was added 40 μl of a solution containing HEPES buffer pH 7.6, 0.26 M; EDTA 0.01 M; NADPH 2.0 mM; insulin, 1.03 mM. The reaction was initiated by adding a 20 μl fraction of the low molecular weight Trx component eluted from the same gel-filtration column and the mixture was incubated for 20 min at 37°C. The reaction was stopped with 500 μl of a solution containing 0.4 mg DTNB/ml and 6 M Guanidine HCI in 0.2 M Tris HCI, pH 8.0, and the absorbance A412 read. Table 1 shows the ability of the S. aureus thioredoxin system to reduce insulin disulfides in the presence of NADPH.
Table 1 Identification of thioredoxin reductase activity in Staph, ylococcus aureus
Reaction/ Components NADPH Trxa TrxB Insulin A -ι2
Trx + - + + 0.493
aThe A412 reading observed when Trx is omitted in the assay, reflects the presence of some Trx and other thiois in the partially purified TrxB preparation employed.
29
Example 2
Purification and Characterization of a Thioredoxin Reductase from S. aureus
TrxB was purified from cell extracts of S. aureus by following the NADPH- dependent reduction of DTNB. An overnight culture of S. aureus strain RN8325-4 grown in TSB (100 ml) at 37°C was used as inoculum (5%) for each of two 2L flasks containing TSB (0.5L). Cells were shaken (200 rpm) for 4 hrs at 37°C before being harvested by centrifugation (Sorvall GSA rotor, 5000 rpm, 15 min). All subsequent handling of the sample prior to chromatography was carried out at 4°C. The cell pellet was resuspended in a minimum of TE buffer (50 mM Tris HCI, pH 8.0, 1 mM EDTA) containing phenylmethylsulphonyl fluoride (PMSF) (1 mM) and lysostaphin (0.5 mg), incubated at 4°C, stirred for 30 min, disrupted further by sonication and then centrifuged (15,000 x g, 20 min) to remove insoluble cellular debris. Streptomycin was added to a final concentration of 1%, stirred for 30 min at 4°C and the nucleic acid precipitate removed by centrifugation. The clear supernatant was brought to 40% saturation with ammonium sulfate, stirred to 15 min, and centrifuged (15,000 x g, 10 min). The resulting supernatant was adjusted to 80% saturation with ammonium sulfate and the precipitate collected by centrifugation. The fraction precipitating between 40-80% ammonium sulfate saturation was dissolved in a small volume of buffer and applied to an AcA44 gel-filtration column for size separation chromatography.
Fractions containing the TrxB activity were easily separated from those containing the Trx activity. Fractions exhibiting TrxB and Trx activity were pooled, dialyzed and applied to a DEAE-Sepharose ion exchange column. The column was washed with the loading buffer (TE) and eluted with a linear gradient of NaCI (0.0- 0.5 M) in TE buffer. Fractions containing the TrxB activity were collected and used for further reactions. The purity of fractions showing TrxB activity was determined by SDS-PAGE. The molecular weight of the monomer was determined to be approximately 35 kDa using SDS-PAGE.
30
Example 3
Cloning of the Gene Encoding S. aureus TrxB
The gene encoding S. aureus TrxB (trxB_Sa) was isolated and sequenced as described below. Generally, the gene was identified by PCR using degenerate primers, shown in Table 2A, based on the conserved N-terminal and C-terminal sequences, shown in Table 2B, of known bacterial thioredoxin reductases. See, e.g., Russell et al. (1988) J. Biol. Chem. 263:9015-9019, for the sequence of E. coli
TrxB; Cohen et al. (1993) J. Bactehol. 175:5159-5167, for the sequence of S. clavuligerus TrxB; Cohen et al. (1994) J. Bactehol. 176:973-984, for the sequence of Penicillium chrysogenum TrxB; Dai ef al. (1996) J. Mol. Biol. 264:1044-1057, for the sequence of Arabidopsis thaliana TrxB; Lubbers et al. (1993) Eur. J. Biochem.
217:791-798, for the sequence of Eubacterium acidominophilum TrxB; and Chae ef al. (1994) J. Biol. Chem. 269:27670-27678, for the sequence of Saccharomyces cerevisiae TrxB. The DNA fragment generated by PCR was labeled and used as a probe in the isolation of a 2.8 kB Xbal fragment from S. aureus genomic DNA that carried the trxB gene. The sequence of the open reading frame and the deduced amino acid sequence are shown in Figure 1 (SEQ ID NO:1) and Figure 2 (SEQ ID
NO:2), respectively.
Table 2A
Degenerate Oligodeoxynucleotide Primers Used in the PCR
Amplification of an Internal Region of the Gene Encoding TrxB
Oligomer Sequence3
P1 5'-ACIACIGAIGTIGA(AG)AA(CT)TT(CT)CC(AGCT)GG-3'
(N-terminal region) (SEQ ID NO:3)
denotes inosine.
31
Table 2B Peptide Regions Specified by Degenerate Oligonucleotide Primers Used in PCR Amplification of an Internal Segment of the Gene Encoding TrxB
Region Sequence
A. Isolation of a Large Internal DNA Fragment of the trxB Gene
Degenerate oligodeoxynucleotides which were designed to encode the N- terminal and C-terminal trxB sequences were used as primers for PCR of S. aureus genomic DNA. The PCR reaction contained the following: 100 ng genomic DNA, 50 μm each of
5'-ACIACIGAIGTIGA(AG)AA(CT)TT(CT)CC(AGCT)GG-3'
(SEQ ID NO:3) and
5'-ACGTCICCIGCIGC(AG)AA(AGCT)AC(AGCT)CC-3'
(SEQ ID NO:4); MgCI2 (1.5 mM); bovine serum albumin (BSA) (5 μg); deoxynucleotide triphosphates (dNTPs) (0.2 mM each); and 1 x PCR buffer (Fermentas, MBI). The reaction mixture was incubated at 94°C (1 min), 55°C (2 min) and 72°C (2 min) for 30 cycles. The resulting 700 bp PCR product was cloned directly using an AT cloning kit (Promega) and sequenced using universal "forward" and "reverse" primers which are homologous to the flanking region of the multiple cloning site within the plasmid pGEMT (the AT cloning vector (Promega)). The cloning vector including the 700 bp PCR product was termed pOI1.
B. Cloning and Seguencing of the Gene Encoding TrxB
The fragment from above was labeled with digoxygenin and used to probe Southern blots of S. aureus genomic DNA digested with various restriction enzymes. A single 2.8 kb Xbal fragment that hybridized to the probe under stringent conditions (50% formamide, 42 C) was subcloned into plasmid pUC18 to form pOI2 and sequenced. Initial sequencing primers were designed to prime within the sequence of the PCR fragment described above and to sequence into the flanking regions.
32
New primers were designed within the new sequences and the nucleotide sequence of the entire gene was thus determined stepwise. All of the sequences were confirmed by sequencing both the coding and non-coding strands.
C. Sequence Analysis of S. aureus trxB
The sequence of the S. aureus trxB gene and the deduced amino acid sequence are shown in Figure 1 (SEQ ID NO:1) and Figure 2 (SEQ ID NO:2), respectively. Using the CLUSTALW Program (Thompson ef al. (1994) Nucl. Acid Res. 22:4673-4680), the S. aureus TrxB amino acid sequence was compared to other bacterial TrxBs. All parameters used were the standard default parameters recommended by CLUSTALW (see, web site http://www2.ebi.ac.uk/clustalw). Sequence identities found were Bacillus subtilis (72%), Listeria monocytogenes (65%), Clostridium litorale (53%), Mycobacterium leprae (45.5%), Streptomyces coelicolor (43.7%), Escherichia coli (41.9%), Mycoplasma genitalis (35%).
P. Heterologous Overexpression of S. aureus trxB in E. coli
The open reading frame encoding S. aureus TrxB is amplified by the PCR reaction using the N-terminal primer 5'-
GGGAATTCCATATGACTGAAATAGATTTTGAT-3* (SEQ ID NO:7) and the C- terminal PCR primer 5'-CCCAAGCTTTTAAGCTTGATCGTTTAA-3' (SEQ ID NO:8). The resulting fragment is digested with Λ/del and HindWl, purified and ligated with vector pET14b (Novagen, Inc. Madison Wl) that is digested with the same two enzymes and purified similarly to produce plasmid pTRSA. An overnight culture (10 mL) of E. coli BL21 (DE3) cells harboring pTRSA is washed twice in 10 ml of TB medium and used as an inoculum for 1 liter of the same medium containing ampicillin (400 mg/mL). The resulting culture is incubated at 37°C until it reaches mid-stationary phase (A600 ~ 1.2), induced to express recombinant TrxB (rTrxB) by the addition of IPTG (to 1 mM) and then incubated for an additional 3 hours at 37°C. The cells are harvested and the recombinant enzyme is purified as described in Example 2 for native TrxB, except that lysozyme (2 mg/mL) is used in place of
33
lysostaphin to assist in disrupting the cells. The purity of the resulting recombinant enzyme is measured by SDS-PAGE and staining with Coomasie brilliant blue.
E. Construction of Gene Replacement Shuttle Vector Plasmid pAUL-A (Chakraborty ef al. (1992) J. Bactehol. 174:568-574; Figure
3), used for trxB inactivation in S. aureus and S. epidermidis, contains a temperature sensitive origin of replication for Staphylococcus such that, when the temperature is raised to 42°C, the plasmid cannot replicate. Additionally, the plasmid contains the origin of replication of pBR322 and is therefore able to propagate in both E. coli and in the above bacteria. If the inactivation plasmid carries a segment of the host chromosome, recombination between the homologous segments will result in the integration of the plasmid. At 42°C, the integrated plasmid can be stably maintained employing selection for the genetic marker, erythromycin resistance, carried on the plasmid sequence. If the homologous chromosomal fragment represents a segment internal to a gene, a single recombinational crossover of the plasmid into the chromosome will cause disruption of the gene and result in the inactivation of the corresponding polypeptide. If the homologous chromosomal fragment contains a deletion internal to a gene, a single recombinational crossover of the plasmid into the chromosome generates a tandem arrangement of wild-type and mutant genes separated by the plasmid sequence; a second recombination event results in loss of one of the copies and the intervening plasmid sequence which, if of the wild-type copy, leads to gene replacement and inactivation of the corresponding polypeptide.
F. Disruption of Chromosomal S. aureus trxB Gene The disruption plasmid, pOI7 (Figure 4), was made as follows. The PCR 700 bp internal ftxB fragment was excised from plasmid pOI1 by digestion with Bam λ\ and Ecol within the multiple cloning site, and inserted into pAUL-A to form pOI7. S. aureus strain RN4220 was transformed with pOI7 by electroporation, as described by Schenk, S. and Laddaga, A. (1992) Microbiol. Lett. 94:133-138, and transformants grown at 30°C or 42°C (the non-permissive temperature) on plates
34
containing erythromycin. Transformants containing a mutant trxB gene due to disruption of the chromosomal gene were selected for directly at 42°C. From some 2000 transformants tested in this way, four grew up at 42°C but only one could be further propagated at this temperature. PCR analysis revealed that in this case, and in other cases like it, no evidence was found for stable integration of the disruption vector at the chromosomal trxB locus. This supports the view that disruption of trxB is a lethal event. Control experiments using the pAUL-A plasmid containing a 800 bp internal segment of the S. aureus glnA gene, showed that stable integrants of the plasmid readily occurred at the glnA chromosomal locus.
G. Replacement of Chromosomal S. aureus trxB Gene
The replacement plasmid was made as follows (see Figures 5A and 5B). The 3.1 kb Pvu\\-Hind\\ tetM (tetracycline resistance) cassette of pRN6680 (Nesin, et al. (1990) Antimicro. Agents. Chemother. 34:2273-2276) was blunt end ligated to the Nru\IEcol2 large fragment of plasmid pOI2 to form pOI4 (Figure 5A). Plasmid pOI2 is pUC18 containing the 2.8 kB trxB Xbal DNA fragment, as described above. Plasmid pOI4 lacks a large internal segment of the trxB gene. The 5.2 kB Asp718- Sall fragment of pOI4 was inserted into pAUL-A and the resulting plasmid, pOI5 (Figure 5B) was used to transform by electroporation S. aureus RN4220. Transformants were grown at 42°C in the presence of erythromycin and tetracycline. The DNAs of six randomly chosen transformants were analyzed by PCR and it was found in each case that the plasmid had integrated into the chromosome by a single crossover event in the DNA flanking region upstream of the trxB gene.
Phage 011 transduction was performed to generate the desired gene replacement, as described by Novick, R.P. Meth. Enzymology 204:587-636. The phage was grown on one of the above integrants at 42°C in the presence of tetracycline and erythromycin and the lysate used to transduce S. aureus RN4220. Transductants, in which the wild-type copy of trxB had been replaced with the mutant copy due to a phage mediated double crossover recombination event, were screened for at 42°C on plates containing tetracycline but lacking erythromycin.
35
None of the 750 transductants scored in this way were found to have lost the plasmid erythromycin marker. PCR analysis showed that the transductants contained both the intact and wild-type trxB copies. Alternatively, one of the above integrant strains was propagated for 100 generations (in the presence of tetracycline and absence of erythromycin) to enable spontaneous elimination of either the wild- type or mutant trxB copies. None of the 750 clones tested were found to have lost the erythromycin marker. These results indicate that loss of the wild-type trxB gene is a lethal event and are consistent with the gene disruption experiments described above. Example 4
Identification of Genes Encoding Thioredoxin Reductase in Staphylococcus epidermidis
The polypeptide sequence of TrxB from S. aureus shown in Figure 2 (and designated hereinafter of TrxB_Sa) was used to search for genes having similar sequences (and thus theoretically the same functional activity as S. aureus TrxB) in a variety of microorganisms. The database search tool BLAST (Altschul, et al. (1990) J. Mol. Biol. 215:403-410) was employed to search the PathoSeq™ database, version 3.0 (Incyte Pharmaceuticals, Palo Alto, CA). Matches were found in the genomic sequence of Staphylococcus epidermidis 0-47 (available from Incyte) in the contiguous sequence (contig) designated SEP1c0392. The open reading frame encoding the entire TrxB in the contig was identified and the corresponding polypeptide product deduced. The gene for TrxB in S. epidermidis (designated trxB_Se) is shown in Figure 6 (SEQ ID NO:9). TrxB_Sa and TrxB_Se were compared by aligning the full-length amino acid sequences using the GAP program. This program considers all possible alignments and gap positions and creates the alignment with the largest number of matched bases and the fewest gaps. A gap creation penalty and gap extension penalty is provided in units of matched bases. The program then creates a gap creation penalty number of matches for each gap it inserts. If a gap extension penalty greater than zero is used, the program also tracks, for each gap inserted, the length of the gap times the
36
gap extension penalty. The GAP program uses the alignment method of Needleman and Wunsch (1970) J. Mol. Biol. 48:443-453.
The alignment of TrxB_Se and TrxB_Sa is shown in Figure 7. The sequences show about 90.4% identity and about 93.6% similarity (e.g., conservative amino acid substitutions). The gap weight was 12, length weight 4, quality 1470, ratio 4.727, average match 2.912, average mismatch -2.003, and gaps 0.
Example 5
Cloning of the S. epidermidis trxB Gene and Overexpression in E. coli The open reading frame encoding the polypeptide TrxB_Se is amplified by
PCR from genomic DNA of S. epidermidis 0-47 using the N-terminal primer
5*-GGGAATTCCATATGACTGAAGTAGATTTTGAT-3'
(SEQ ID NO:7) and the C-terminal reverse primer
5'-CCCAAGCTTπAAπATCTTπAATTCTGT-3' (SEQ ID NO:8). The resulting amplified fragment is digested with the enzymes Ndel\ and Hind\\\ and ligated with the vector pET22B(+) (Novagen, Madison Wl) digested with the same enzymes.
The resulting plasmid, designated pTRSE, in introduced in E. coli BL21 (DE3) essentially as in Example 3D. The E. coli strain carrying pTRSE is grown and the
TrxB_Se enzyme is isolated essentially as described in Example 3D and analyzed as in Example 1.
Example 6 Inactivation of trxB Se A 750 bp segment internal to trxB_Se, corresponding to nt 11471-12221 , lacking N-terminal and C-terminal sequences coding for essential trxB nucleotide binding domains, is amplified by PCR employing the primers
5'-GGGAATTCGTATATGCATCTCGTGCCAAT-3' (SEQ ID NO:7) which contains an
EcoRI site near the 5' end and
5'-CCCAATTGTACCTCGTACTTTAGTACTCA-3' (SEQ ID NO:8) which contains a
Hind\\\ site near the 5' end. The amplified fragment is digested with the enzymes EcoRI and Hind\\\, and ligated into the vector pAUL-A which is digested with the
37
same enzymes. The resulting plasmid, designated pTRSE-int, is introduced into E. coli. The E. coli strain carrying pTRSE-int is grown and harvested and the plasmid pTRSE-int isolated. The plasmid is electroporated into S. epidermidis following the procedures described in Augustin, J. and Goetz, F. (1990) FEMS Microbiol. Lett. 68:203-208, employing selection for erythromycin resistance. A culture of S. epidermidis/pTRSE-\r\t is grown to mid-log phase in the presence of erythromycin then placed on TSA plates containing erythromycin. To verify that trxB_Se is an essential gene for growth, the plates are incubated at 42°C and the surviving colonies analyzed for integration of the pTRSE-int plasmid at the chromosomal trxB locus due to a single recombinational crossover event. Inability to isolate cells containing a disrupted trxB gene indicates that trxB_Se is an essential gene for growth.
Example 7 High Throughput Assay to Identify Inhibitors
Of a Microbial Thioredoxin Reductase
An insulin assay (modified from A. Holmgren and M. Bjornstedt, (1995)
Methods in Enzymology 252:199-208) is used as a sensitive method to monitor the red ox-activity of thioredoxin (T) in enabling the NADPH-dependent reduction of insulin disulfides in the presence of thioredoxin reductase (TrxB). In this reaction,
TrxB specifically reduces T-S2 to T-(SH)2 using NADPH [reaction (1)]. The formed T-
(SH)2 is a powerful reductant of native insulin [reaction (2)].
TrxB T-S2 + NADPH + H+ T-(SH2) + NADP+ (1)
Spontaneous T-(SH)2 + Insulin T-S2 + lnsulin-(SH2) (2)
The amount of reduced insulin is determined spectrophotometrically at 412 nm after denaturation with 6M guanidine-HCI in the presence of DTNB step 1 in
38
scheme. The reduction of insulin in a reaction that is T-dependent and TrxB- independent is tested spectrophotometrically at 650 nm as an increase in turbidity due to the precipitation of the free (reduced) insulin chain B, step 2 in scheme. A. Step I: One hundred μl of a reaction mixture containing 0.3 mM insulin, 100 mM
HEPES pH 7.5, 3 mM EDTA, 0.5 NADPH, and 1-20 μg of S. aureus TrxB is added to the wells of a series of 96 well microtiter plates. Thioredoxin is omitted from well 1. Wells 3 through 94 contain one of the following: a few μg of the test compound singly, either as a dry powder or in 1-5 μl of 50 mM Tris-HCI, pH 7.8, 50 mM NaCI buffer; a few μg each of a mixture of the test compounds either as a dry powder or in a few μl of 50 mM Tris-HCI, pH 7.8, 50 mM NaCI buffer, for uncharacterized mixtures of compounds derived from bacteria, fungi, plants, marine organisms and present in a few μl of water, buffer, or DMSO. In the first two cases, the amount of compound employed is adjusted so that after all the additions are made the concentration of each compound is in the range of 1-10 μM. Wells 95 and 96 do not contain any compound. To well 1 and to wells 3-96 is added 10 μl of S. aureus TrxB solution containing approximately 300 pmoles in order to start the reaction. Water is added before the addition of TrxB to adjust the volume of each well to 150 μl. The plate is incubated at 37°C for 20 min. The reaction is terminated by the addition of 150 μl of 0.4 mg/ml DTNB/6 M guanidine hydrochloride in 0.2 M Tris-HCI, pH 8.0 and the absorbance at 412 nm is measured. All compounds that show inhibition of the DTNB reaction are further tested in step II.
B. Step II: (Modified) from A. Holmgren (1979) J. Biol. Chem. 254:9627-9632)
Two hundred and fifty μl of the assay mixture containing a freshly prepared solution of bovine insulin, 1 mg/ml of 0.1 M potassium phosphate pH 7.0, 2 mM
EDTA, is added to all the wells of a series of 96 well microtiter plates. Thioredoxin solution, 10 μl, is added to wells 3-96 to reach 3-8 μM concentration. Wells 3 through 94 also contain one of the following samples that exhibited inhibition of the
DTNB reaction in step I: a few μg of single compounds either as a dry powder or in
39
1-5 μl of 50 mM Tris-HCI, pH 7.8, 50 mM NaCI buffer, a few μg of a mixture of compounds either as a dry powder or in a few μl of 50 mM Tris-HCI, pH 7.8, 50 mM NaCI buffer; uncharacterized mixtures of compounds derived from bacteria, fungi, plants, marine organisms in a few μl of water, buffer, or DMSO. In the first two cases, the amount of compound employed is adjusted so that after all the additions are made, the concentration of each is in the range of 1-10 μM. Wells 95 and 96 do not contain any compound or extract. The reaction is started by the addition of 10 μl dithiothreitol (DTT) to wells 2-95 to reach a final concentration of 0.3-0.5 mM. The plate is thoroughly agitated and placed in a plate reader and the absorbance at 650 nm is determined. The absorbance is read at intervals of 0.5 min for 80 min. In a typical reaction in the control well 2, containing only DTT and insulin, no precipitation is observed until after about 70 min. In the presence of T and DTT, precipitation appears after 10-15 min.
In order to evaluate whether a compound is a potential TrxB inhibitor, the compound should exhibit the properties depicted in the flow chart shown as Figure 8.
Thus, an isolated S. aureus TrxB polypeptide, DNA coding therefor and methods of using the same to identify inhibitors of TrxB, are provided. Although preferred embodiments of the subject invention have been described in some detail, it is understood that obvious variations can be made without departing from the spirit and the scope of the invention as defined by the appended claims.
Claims
1. An isolated Staphylococcus thioredoxin reductase (TrxB) poiypeptide.
2. The TrxB polypeptide of claim 1 comprising an amino acid sequence selected from the group consisting of (a) the amino acid sequence of SEQ ID NO:2, (b) the amino acid sequence of SEQ ID NO: 10, and (3) an amino acid sequence having 75% identity to either (a) or (b).
3. An isolated polynucleotide encoding the Staphylococcus TrxB of Claim
1.
4. An isolated polynucleotide encoding the Staphylococcus TrxB of Claim
2.
5. A recombinant vector comprising the polynucleotide of Claim 3 operably linked to control sequences that direct the transcription of the polynucleotide whereby said polynucleotide is expressed in a host cell.
6. A recombinant vector comprising the polynucleotide of Claim 4 operably linked to control sequences that direct the transcription of the polynucleotide whereby said polynucleotide is expressed in a host cell.
7. A host cell comprising the vector of Claim 5.
8. A host cell comprising the vector of Claim 6.
41
9. A method for producing a Staphylococcus TrxB polypeptide comprising: culturing the host cell of Claim 7 under conditions that allow the production of the TrxB polypeptide; and recovering the TrxB polypeptide.
10. A method for producing a Staphylococcus TrxB polypeptide comprising: culturing the host cell of Claim 8 under conditions that allow the production of the TrxB polypeptide; and recovering the TrxB polypeptide.
11. An oligonucleotide probe capable of specifically hybridizing to a nucleic acid molecule encoding a Staphylococcus TrxB, said probe having about 8 to about 50 contiguous nucleotides of the polynucleotide of Claim 3.
12. An oligonucleotide probe capable of specifically hybridizing to a nucleic acid molecule encoding a Staphylococcus TrxB, said probe having about 8 to about 50 contiguous nucleotides of the polynucleotide of Claim 4.
13. An antibody reactive with a Staphylococcus thioredoxin reductase (TrxB).
14. The antibody of Claim 13, wherein said antibody is a monoclonal antibody.
15. The antibody of Claim 13, wherein said antibody is a polyclonal antibody.
42
16. A method of detecting the presence of Staphylococcus in a test sample suspected of containing Staphylococcus, comprising:
(a) contacting the test sample with the oligonucleotide probe of claim 11 , under conditions which allow a Staphylococcus polynucleotide, when present in the test sample, to hybridize with said oligonucleotide probe to form a hybrid complex; and
(b) detecting the presence or absence of said hybrid complex, as an indication of the presence of Staphylococcus in the test sample.
17. A method of detecting the presence of Staphylococcus in a test sample suspected of containing Staphylococcus, comprising:
(a) contacting the test sample with the oligonucleotide probe of claim 12, under conditions which allow a Staphylococcus polynucleotide, when present in the test sample, to hybridize with said oligonucleotide probe to form a hybrid complex; and
(b) detecting the presence or absence of said hybrid complex as an indication of the presence of a Staphylococcus in the test sample.
18. A method of detecting the presence of Staphylococcus in a test sample suspected of containing Stapylococcus, comprising:
(a) contacting the test sample with the antibody of claim 13, under conditions which allow a Staphylococcus TrxB, when present in the test sample, to bind to said antibody to form an antibody-TrxB complex; and
(b) detecting the presence or absence of said antibody-TrxB complex, as an indication of the presence of Staphylococcus in the test sample.
43
19. A method of detecting Staphylococcus in a test sample suspected of containing Staphylococcus, comprising:
(a) incubating the test sample with a disulfide-containing substrate in the presence of thioredoxin and NADPH, under conditions that favor reduction of the disulfide-containing substrate, to produce a detectable signal when a Staphylococcus thioredoxin reductase is present;
(b) detecting the presence or absence of the signal; and
(c) correlating the presence of the signal with the presence of Staphylococcus in the test sample.
20. A diagnostic test kit comprising:
(a) a Staphylococcus TrxB polypeptide according to Claim 1 ; and
(b) instructions for conducting the diagnostic test.
21. A diagnostic test kit comprising:
(a) an oligonucleotide probe according to Claim 11 ; and
(b) instructions for conducting the diagnostic test.
22. A diagnostic test kit comprising:
(a) an antibody according to Claim 13; and
(b) instructions for conducting the diagnostic test.
44
23. A method for identifying a compound that modulates Staphylococcus thioredoxin reductase (TrxB) activity, comprising:
(a) providing a Staphylococcus TrxB polypeptide capable of catalyzing the specific reduction of thioredoxin with the concomitant oxidation of NADPH to NADP+;
(b) contacting a test compound with the TrxB polypeptide in the presence of thioredoxin, NADPH and a disulfide-containing substrate, under conditions that favor reduction of the disulfide-containing substrate;
(c) monitoring the presence of free sulfhydryl groups formed by the reduction of disulfides of the disulfide-containing substrate, as a measure of TrxB activity, thereby identifying a compound that modulates Staphylococcus TrxB activity.
24. The method of Claim 23, wherein the disulfide-containing substrate is insulin.
25. The method of Claim 23, wherein the disulfide-containing substrate is 5,5'-dithio-ib/'s-2-nitrobenzoic acid.
26. A compound identified by the method of Claim 23.
27. A composition comprising the compound of Claim 26 and a pharmaceutically acceptable excipient.
28. A method of treating a Staphylococcus infection in an infected subject, comprising administering to said subject an effective antibacterial amount of the composition of Claim 27.
29. The method of Claim 28, wherein the infection is a Staphylococcus aureus infection.
45
30. A method for isolating a thioredoxin reductase (TrxB) polypeptide from a Staphylococcus cell culture extract, comprising:
(a) performing a protein precipitation step with the cell culture extract to yield a first TrxB mixture;
(b) subjecting the first TrxB mixture to gel-filtration chromatography;
(c) identifying fractions from step (b) with TrxB activity; and
(d) performing anion-exchange chromatography on the fractions with TrxB activity to yield a product with a greater concentration of TrxB than the first TrxB mixture.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US7652598P | 1998-03-02 | 1998-03-02 | |
US60/076,525 | 1998-03-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1999045123A1 true WO1999045123A1 (en) | 1999-09-10 |
Family
ID=22132572
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1999/004512 WO1999045123A1 (en) | 1998-03-02 | 1999-03-02 | Recombinant staphylococcus thioredoxin reductase, and inhibitors thereof useful as antimicrobial agents |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO1999045123A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001077309A2 (en) * | 2000-04-06 | 2001-10-18 | Pharmacia & Upjohn Company | Crystallization and structure determination of staphylococcus aureus thioredoxin reductase |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997023628A1 (en) * | 1995-12-22 | 1997-07-03 | The University Of British Columbia | Staphylococcus aureus coenzyme a disulfide reductase, and inhibitors thereof useful as antimicrobial agents |
EP0786519A2 (en) * | 1996-01-05 | 1997-07-30 | Human Genome Sciences, Inc. | Staphylococcus aureus polynucleotides and sequences |
-
1999
- 1999-03-02 WO PCT/US1999/004512 patent/WO1999045123A1/en active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997023628A1 (en) * | 1995-12-22 | 1997-07-03 | The University Of British Columbia | Staphylococcus aureus coenzyme a disulfide reductase, and inhibitors thereof useful as antimicrobial agents |
EP0786519A2 (en) * | 1996-01-05 | 1997-07-30 | Human Genome Sciences, Inc. | Staphylococcus aureus polynucleotides and sequences |
Non-Patent Citations (3)
Title |
---|
DATABASE EMBL NUCLEOTIDE SEQU 1 January 1900 (1900-01-01), XP002112444, Database accession no. AJ223781 * |
DATABASE TREMBL PROTEIN SEQUE 1 January 1900 (1900-01-01), XP002112443, Database accession no. O54079 * |
HOLMGREN A. AND BJÖRNSTED M.: "Thioredoxin and Thioredoxin Reductase", METHODS IN ENZYMOLOGY, vol. 252, no. part B, 1995, pages 199 - 208, XP002112640 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001077309A2 (en) * | 2000-04-06 | 2001-10-18 | Pharmacia & Upjohn Company | Crystallization and structure determination of staphylococcus aureus thioredoxin reductase |
WO2001077309A3 (en) * | 2000-04-06 | 2002-04-25 | Upjohn Co | Crystallization and structure determination of staphylococcus aureus thioredoxin reductase |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Booker et al. | Cloning, sequencing, and expression of the adenosylcobalamin-dependent ribonucleotide reductase from Lactobacillus leichmannii. | |
Zwiefka et al. | Transcription termination factor rho: the site of bicyclomycin inhibition in Escherichia coli | |
Dale et al. | Characterization of the gene for the chromosomal dihydrofolate reductase (DHFR) of Staphylococcus epidermidis ATCC 14990: the origin of the trimethoprim-resistant S1 DHFR from Staphylococcus aureus? | |
Ross et al. | Cloning, sequence and overexpression of NADH peroxidase from Streptococcus faecalis 10C1: structural relationship with the flavoprotein disulfide reductases | |
Gerlach et al. | Extracellular superoxide dismutase from Streptococcus pyogenes type 12 strain is manganese-dependent | |
JP2001502910A (en) | Enzymatic coenzyme cycling using soluble pyridine nucleotide transhydrogenase | |
Basu et al. | Purification and partial characterization of a penicillin-binding protein from Mycobacterium smegmatis | |
US5985643A (en) | Auxiliary gene and protein of methicillin resistant bacteria and antagonists thereof | |
US6767536B1 (en) | Recombinant Staphylococcus thioredoxin reductase and inhibitors thereof useful as antimicrobial agents | |
Moore et al. | Expression and purification of aspartate β-semialdehyde dehydrogenase from infectious microorganisms | |
WO2007127735A2 (en) | Prokaryotic host cells for expressing proteins rich in disulfide bonds | |
JP6267285B2 (en) | Recombinant glycine N-acyltransferase for therapy | |
Pollock et al. | Molecular cloning and expression of biotin sulfoxide reductase from Rhodobacter sphaeroides forma sp. denitrificans | |
McFARLAN et al. | Purification, characterization and revised amino acid sequence of a second thioredoxin from Corynebacterium nephridii | |
CA2241105A1 (en) | Staphylococcus aureus coenzyme a disulfide reductase, and inhibitors thereof useful as antimicrobial agents | |
Aguilera Gil et al. | NAD+-dependent post-translational modification of Escherichia coli glyceraldehyde-3-phosphate dehydrogenase | |
WO1999045123A1 (en) | Recombinant staphylococcus thioredoxin reductase, and inhibitors thereof useful as antimicrobial agents | |
Olausson et al. | Site-directed mutagenesis of tyrosine residues at nicotinamide nucleotide binding sites of Escherichia coli transhydrogenase | |
Chiu et al. | Amino acid residues involved in the functional integrity of Escherichia coli methionine aminopeptidase | |
US20230183712A1 (en) | Methods for engineering amino acid ammonia lyase enzymes and enzymes thereby obtained | |
US6107068A (en) | Coenzyme A disulfide reductase, and inhibitors thereof useful as antimicrobial agents | |
US20040081646A1 (en) | Group B Streptococcal phage lysin | |
Jiang et al. | Optimized Heterologous Expression of Glutathione Reductase from CyanobacteriumAnabaenaPCC 7120 and Characterization of the Recombinant Protein | |
US6870041B1 (en) | MurE protein and gene of pseudomonas aeruginosa | |
US6949336B1 (en) | Murf gene and enzyme of Pseudomonas aeruginosa |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): CA JP MX |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
122 | Ep: pct application non-entry in european phase |